var title_f19_0_19456="Pelvic floor muscle exercises";
var content_f19_0_19456=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/0/19456/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19456/contributors\" id=\"au60\">",
"       Linda Brubaker, MD, FACS, FACOG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/0/19456/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19456/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/0/19456/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19456/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?19/0/19456?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The pelvic muscles work to control the release of urine. Like other muscles, they can become weakened over time as a result of childbirth, surgery, and aging. People with bladder control problems can improve urinary control through pelvic muscle exercises (also called Kegel exercises).",
"    </p>",
"    <p>",
"     If you want to use pelvic muscle exercises, speak to your healthcare provider to determine if the exercises would be helpful, and also to receive instructions about how to perform the exercises correctly.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PELVIC MUSCLE EXERCISE TECHNIQUE",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       First, you will need to learn which muscles to tighten. To do this, tighten your pelvic muscles while you are urinating to stop the flow of urine. Tighten and relax your muscles to start and stop your flow of urine several times. That way you will learn which muscles are the ones you should tighten. Do this ONLY a few times while you are learning. Normally, when you do the exercises you should NOT stop the flow of your urine, because this can hurt your bladder.",
"       <br/>",
"       <br/>",
"       After you learn which muscles to tighten, you can do the exercises in any position (sitting in a chair or lying down). You do not need to do them while you are in the bathroom.",
"      </li>",
"      <li>",
"       Second, hold the pelvic muscle contraction approximately 8 to 10 seconds, and then relax the muscles; relaxing the muscles is as important as contracting. In the beginning, it may not be possible to hold the contraction for more than one second.",
"       <br/>",
"       <br/>",
"       Perform 8 to 12 exercises three times per day. Try to do this every day, but no less than three or four times a week. Continue this regimen for at least 15 to 20 weeks.",
"      </li>",
"      <li>",
"       Over time, try to hold the contraction harder and for a longer time. You will need to continue these exercises indefinitely to have a lasting effect, similar to other forms of exercise.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some people benefit from working with a physical therapist or nurse to receive more detailed instructions and to ensure that you use the correct technique. In addition, these providers may use biofeedback to improve your exercise technique and strength. Biofeedback uses a computer monitor to show you as the muscles contract and relax, and also indicates if you use the wrong muscles.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PELVIC MUSCLE EXERCISE RESULTS",
"     </span>",
"    </p>",
"    <p>",
"     Studies have shown that, if done correctly, pelvic muscle exercises can be effective in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you leak urine with",
"       <span class=\"nowrap\">",
"        coughing/laughing/sneezing.",
"       </span>",
"       Contract your muscles when you are about to",
"       <span class=\"nowrap\">",
"        cough/laugh/sneeze",
"       </span>",
"       to avoid leaking.",
"      </li>",
"      <li>",
"       If you have a sudden urge to run to the bathroom, sit or stand still and contract your pelvic muscles. After the urge diminishes, you can then proceed to the toilet.",
"      </li>",
"      <li>",
"       If you have mild fecal leakage (leakage of stool).",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These exercises are less helpful for people with severe leakage with",
"     <span class=\"nowrap\">",
"      laughing/coughing/sneezing.",
"     </span>",
"     Exercises are not helpful at all for people with other types of urinary incontinence, including overflow incontinence (when the bladder cannot empty completely and leaks when it becomes overly full). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"      \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"      \"Patient information: Urinary incontinence treatments for women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Most people notice an improvement after three to four months of practicing pelvic muscle exercises. If these exercises are not helpful, please speak with a healthcare provider. Other treatments are available and may be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H41\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25403196\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/60/11202?source=see_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/9/35987?source=see_link\">",
"      Patient information: Urinary incontinence in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/62/44001?source=see_link\">",
"      Patient information: Pelvic organ prolapse (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25403222\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/19/19764?source=see_link\">",
"      Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28122?source=see_link\">",
"      Nocturia: Clinical presentation, diagnosis, and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mayo Clinic",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"      www.mayoclinic.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Family Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.familydoctor.org/\">",
"      www.familydoctor.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidney.niddk.nih.gov/kudiseases/a-z.asp\">",
"      file://kidney.niddk.nih.gov/kudiseases/a-z.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Association for Continence",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-BLADDER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nafc.org/\">",
"      www.nafc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Simon Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.simonfoundation.org/\">",
"      www.simonfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?19/0/19456/abstract/1\">",
"      1",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?19/0/19456?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19456/abstract/1\">",
"      Hay-Smith EJ, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2006; :CD005654.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f19_0_19456=[""].join("\n");
var outline_f19_0_19456=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PELVIC MUSCLE EXERCISE TECHNIQUE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PELVIC MUSCLE EXERCISE RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f19_0_19457="Straddle injury6";
var content_f19_0_19457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Trauma of child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note 2nd degree laceration noted on separation and traction of labia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19457=[""].join("\n");
var outline_f19_0_19457=null;
var title_f19_0_19458="Ulcer after gastric bypass";
var content_f19_0_19458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Marginal ulcer after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large marginal ulcer after gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher S Huang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19458=[""].join("\n");
var outline_f19_0_19458=null;
var title_f19_0_19459="Eczema herpeticum face";
var content_f19_0_19459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eczema herpeticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhagic crusts and vesicles due to herpes simplex virus infection are present on the face of this infant with underlying atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19459=[""].join("\n");
var outline_f19_0_19459=null;
var title_f19_0_19460="Ketorolac (ophthalmic): Patient drug information";
var content_f19_0_19460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketorolac (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=see_link\">",
"     see \"Ketorolac (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=see_link\">",
"     see \"Ketorolac (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8346944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Acuvail&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8346945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acular LS&reg;;",
"     </li>",
"     <li>",
"      Acular&reg;;",
"     </li>",
"     <li>",
"      Apo-Ketorolac&reg; Ophthalmic;",
"     </li>",
"     <li>",
"      ratio-Ketorolac",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3828342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketorolac tromethamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Burning.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12235 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19460=[""].join("\n");
var outline_f19_0_19460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8346945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031274\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031273\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031278\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031279\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031281\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031276\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031277\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031282\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031283\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/59/41909?source=related_link\">",
"      Ketorolac (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_0_19461="Palpable purpura from vasculitis";
var content_f19_0_19461=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Palpable purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Non-blanching, palpable purpuric skin lesions found over the lower extremity of a patient with a small vessel vasculitis affecting the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph F Merola, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19461=[""].join("\n");
var outline_f19_0_19461=null;
var title_f19_0_19462="Penis anatomy";
var content_f19_0_19462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Anatomy of the penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 580px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19462=[""].join("\n");
var outline_f19_0_19462=null;
var title_f19_0_19463="Plaque psoriasis 1";
var content_f19_0_19463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87442&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Plaque psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Elevated red plaques with a sharply defined margin and symmetric distribution in a patient with chronic plaque psoriasis.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19463=[""].join("\n");
var outline_f19_0_19463=null;
var title_f19_0_19464="Management of brain metastases in breast cancer";
var content_f19_0_19464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of brain metastases in breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Nancy U Lin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Naren Ramakrishna, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19464/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/0/19464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the second most common cancer associated with brain metastases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/1\">",
"     1",
"    </a>",
"    ]. As patients with advanced breast cancer live longer, the incidence of brain metastases appears to be increasing. In a subset of women, progression in the central nervous system (CNS) has become the major life-limiting problem.",
"   </p>",
"   <p>",
"    The risk factors, prognosis, and management of brain metastases in breast cancer are presented here. An overview of the presentation, diagnosis, and management of brain metastases (across tumor types) is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"       \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"       \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of central nervous system (CNS) relapse among patients with breast cancer varies significantly by disease stage. Among women presenting with early stage breast cancer, less than 3 percent will go on to develop brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In contrast, symptomatic brain metastases are diagnosed in 10 to 16 percent of patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Factors associated with an increased likelihood of CNS relapse include age under 40 years, pulmonary metastases, and African American ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/1,3-7\">",
"     1,3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the breast cancer subtype appears to be associated with the incidence of brain metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/2,6,8-19\">",
"     2,6,8-19",
"    </a>",
"    ]. In a cohort study of 1434 women treated with breast conserving therapy plus systemic chemotherapy, brain metastases developed in 36 (2.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the risk of brain metastases at ten years differed by breast cancer subtype:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Luminal A &mdash; 0.7 percent",
"     </li>",
"     <li>",
"      Luminal B &mdash; 12 percent",
"     </li>",
"     <li>",
"      Luminal-HER2 positive &mdash; 8 percent",
"     </li>",
"     <li>",
"      HER2 &mdash; 12 percent",
"     </li>",
"     <li>",
"      Triple-negative &mdash; 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The brain is increasingly reported as the first site of relapse in women with HER2-positive breast cancer treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , whether administered in the adjuvant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] or metastatic settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. However, the relationship between CNS events and receipt of HER2-directed agents (eg, trastuzumab) for women with HER2-positive metastatic breast cancer is not clear. Although a higher rate of CNS events has been reported, it seems unlikely that the administration of HER2-directed agents &ldquo;increases&rdquo; this risk. Because trastuzumab was shown to reduce recurrence rates in the adjuvant setting, the higher rate of CNS events is probably more related to the increased survival of patients, coupled with the inability of trastuzumab to cross the blood brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and CNS events is illustrated in these examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 meta-analysis of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      trials reported an increased incidence of brain metastases associated with adjuvant trastuzumab use (odds ratio 1.58, 95% CI 1.08-2.30) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/20\">",
"       20",
"      </a>",
"      ]. However, the overall risk of brain metastases was low in both of the trastuzumab and control groups in all of the trials.",
"     </li>",
"     <li>",
"      A separate analysis of over 3400 patients who participated in the HERA randomized trial of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      versus observation reported that adjuvant trastuzumab did not increase the risk of a CNS event as the initial recurrence (2 percent in both arms) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/21\">",
"       21",
"      </a>",
"      ]. In addition, adjuvant trastuzumab use was associated with a lower incidence of CNS events in subsequent years compared to those who were not treated with trastuzumab (47 versus 57 percent, respectively), although this difference was not statistically significant (p=0.06). &nbsp;",
"     </li>",
"     <li>",
"      The incidence of CNS metastases was 35 percent among 122 patients with HER2-positive metastatic breast cancer treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      ; CNS disease was present at the time of diagnosis or discovered during treatment in 9 patients (21 percent) and 34 (79 percent) patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with triple-negative breast cancer have an increased risk of brain metastases as the initial site of metastases or following a diagnosis of breast cancer. In one study, the 5-year cumulative incidence of brain metastases as a first site of recurrence was 3, 5, and 10 percent with stage I, II, and III disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/18\">",
"     18",
"    </a>",
"    ]. In other studies, the incidence of brain metastases at or following the diagnosis of metastatic breast cancer ranges between 25 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/6,19\">",
"     6,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22654193\">",
"    <span class=\"h1\">",
"     PRIMARY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the primary treatment of patients with brain metastasis is standard, regardless of primary cancer type, with options based on prognosis. In addition, symptom control is of primary importance and includes control of peritumoral edema and increased intracranial pressure with corticosteroids, treatment and prevention of seizures, and management and prevention of venous thromboembolic disease. These topics are covered in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=see_link\">",
"       \"Management of vasogenic edema in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18843855\">",
"    <span class=\"h2\">",
"     HER2-positive metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with brain metastases from HER2-positive disease, the administration of systemic therapy may delay the use of whole brain radiation therapy (RT) and the associated risk of neurologic toxicity. Although limited data are available, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    appears to be a reasonable alternative to whole brain RT for these patients. The potential benefit of this combination was demonstrated in the LANDSCAPE trial in which 45 patients with previously untreated brain metastases from HER2-positive metastatic disease were treated with lapatinib (1250 mg daily) plus capecitabine (2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 to 14 of a 21-day cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/22\">",
"     22",
"    </a>",
"    ]. Over 90 percent of patients had previously been exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . With a median follow-up of 21 months, 29 of 44 evaluable patients (66 percent) had a partial response. The median time to progression was 5.5 months, and in 32 patients, the first site of progression was in the CNS. Overall survival at six months was 91 percent. Serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicity was recorded in 22 (49 percent) patients including diarrhea (n=9), hand-foot syndrome (n=9), fatigue (n=6), and rash (n=2). These data suggest that the combination of lapatinib and capecitabine is active as a first-line treatment for patients with brain metastases from HER2-positive breast cancer.",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    should be the preferred regimen in the first-line treatment of patients with brain metastases from HER2-positive disease is unknown. Further evaluation comparing this combination to standard therapy (eg, whole brain RT) is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'WBRT after definitive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, results from the LANDSCAPE trial support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    as a potential alternative to RT in this patient population, assuming close follow up and with an acknowledgement that the data are limited. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF RECURRENT/PROGRESSIVE METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initial treatment for brain metastases due to breast cancer, both surgery and stereotactic radiosurgery can be used to retreat patients who develop recurrent, symptomatic CNS disease and have stable extracranial disease following their initial treatment for brain metastases. Careful selection of patients is critical in this setting. As with the initial evaluation, the absence of active systemic disease and a Karnofsky performance score of at least 70 are important (",
"    <a class=\"graphic graphic_table graphicRef77561 \" href=\"UTD.htm?7/63/8187\">",
"     table 1",
"    </a>",
"    ). Factors indicating a probable poor outcome include a short time to recurrence and age less than 40 years. General issues on the treatment of recurrent or progressive metastases and the use of systemic therapy are covered separately. Specific treatments for patients with breast cancer are reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of brain metastases in favorable prognosis patients\", section on 'Recurrent disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=see_link\">",
"     \"Systemic therapy for brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539835705\">",
"    <span class=\"h2\">",
"     Stereotactic radiosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For selected patients with a good performance status, stereotactic radiosurgery (SRS) is a reasonable option to treat recurrent central nervous system (CNS) metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/23\">",
"     23",
"    </a>",
"    ]. In one study, the outcomes following SRS were reported in 79 patients who had initially been treated with whole brain radiation therapy (96 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical resection (18 percent) for brain metastases. Although less than half had stable systemic disease at the time of SRS, 97 percent had a good Karnofsky performance score (KPS) (",
"    <a class=\"graphic graphic_table graphicRef57945 \" href=\"UTD.htm?3/29/3549\">",
"     table 2",
"    </a>",
"    ) of at least 70 percent. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median CNS recurrence free survival was 6 months (range, 4 to 11 months). With a median follow-up of 17 months, 61 percent experienced CNS progression with simultaneous systemic progression in 16 percent.",
"     </li>",
"     <li>",
"      Median overall survival was 10 months (range, 4 to 18 months).",
"     </li>",
"     <li>",
"      Factors associated with an increased risk of death including HER2-negative disease (hazard ratio [HR] 2.4, 95% CI 1.3-3.7) and progressive systemic disease (HR 2.7, 95% CI 1.4-5.2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses of both parenchymal and leptomeningeal metastases have been documented in case reports to multiple hormonal therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , and the aromatase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cytotoxic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although few of the commonly used agents for breast cancer penetrate the intact blood-brain barrier to a significant degree, many of the same agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) have been described to have activity against CNS metastases, likely as a result of increased vessel permeability associated with tumor vasculature (",
"    <a class=\"graphic graphic_table graphicRef81191 \" href=\"UTD.htm?9/6/9326\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In a relatively older case series of 100 consecutive breast cancer patients treated with a variety of chemotherapy regimens, an objective response rate of 50 percent and a median duration of response of seven months were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/29\">",
"     29",
"    </a>",
"    ]. However, in this study, patients were untreated compared to the current era: less than 10 percent of patients had received adjuvant chemotherapy and approximately half had not received chemotherapy for metastatic disease.",
"   </p>",
"   <p>",
"    Other cytotoxic agents that have been investigated in the treatment of brain metastases include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and platinum agents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. A number of agents are in clinical trials, including GRN1005 and several anthracycline derivatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , as well as other novel targeted therapies, show promise in the treatment of brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18843777\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective, single-arm clinical trials have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    , an orally active small molecule inhibitor of epidermal growth factor receptor (EGFR) and HER2, in patients with refractory CNS metastases from HER2-positive metastatic breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The objective response rate to lapatinib monotherapy in these trials was modest, though a few patients achieved prolonged clinical benefit. In the larger of these trials, a subset of 50 patients went on to receive the combination of lapatinib and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    at the time of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/37\">",
"     37",
"    </a>",
"    ]. Of these, 10 (20 percent) achieved an objective response in the CNS, while maintaining stable or responsive disease in extracranial sites.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    has been subsequently evaluated in several trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       Lapatinib",
"      </a>",
"      Expanded Access Program (LEAP), in which 138 patients with progressive CNS metastases (including patients with prior",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      exposure) were enrolled, the CNS objective response rate was 18 percent with combined lapatinib plus capecitabine [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Italian investigators reported a 32 percent partial response rate with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      in 22 patients with brain metastases from HER2-positive breast cancer, all of whom had previously received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, and given the results of the LANDSCAPE trial in the first-line setting, these data support a role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"     lapatinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in the treatment of women with recurrent brain metastases from HER2-positive breast cancer. (See",
"    <a class=\"local\" href=\"#H18843855\">",
"     'HER2-positive metastatic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18843770\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, patients with brain metastases have been excluded from trials of antiangiogenic agents, out of a concern for intracranial hemorrhage. The approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody that binds vascular endothelial growth factor (VEGF), for patients with glioblastoma has spurred interest in this class of agents for brain metastases. Data from patients with non-small cell lung cancer suggest that bleeding events are relatively uncommon and support the careful investigation of these agents in breast cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/40\">",
"     40",
"    </a>",
"    ]. A phase II study of bevacizumab in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for progressive breast cancer brain metastases is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/41\">",
"     41",
"    </a>",
"    ]. Bevacizumab is also being investigated for the treatment of radiation necrosis of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328010061\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other targeted agents may hold promise for the treatment of CNS metastases, including poly (ADP-Ribose) polymerase (PARP) inhibitors, histone deacetylase (HDAC) inhibitors, small molecule inhibitors of HER2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VEGFR, and PI3K inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328009664\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective analyses suggest that the prognosis of brain metastases in patients with breast cancer is improving, and this appears to be primarily a result of advances in systemic therapy, which have led to better control of disease outside the CNS. In historical series, the median survival for patients with brain metastases treated with whole brain radiation therapy (WBRT) was less than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In contrast, a retrospective study of 112 breast cancer patients diagnosed with brain metastases between 1997 and 2007 showed a median survival of 14.4 months (for the entire cohort); among patients with HER2-positive breast cancer, it was 23.1 months. This markedly exceeds median survival estimates from patients treated prior to the widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for metastatic, HER2-positive breast cancer (approximately three months), and therefore likely represents the effect of improved systemic control on breast cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/8,46\">",
"     8,46",
"    </a>",
"    ]. Other investigators have noted similar results (",
"    <a class=\"graphic graphic_table graphicRef80803 \" href=\"UTD.htm?37/8/38028\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/9,10,14,47-50\">",
"     9,10,14,47-50",
"    </a>",
"    ]. Unfortunately, the prognosis for patients with brain metastases with triple-negative breast cancer remains poor (",
"    <a class=\"graphic graphic_table graphicRef58556 \" href=\"UTD.htm?34/3/34875\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/19,50-52\">",
"     19,50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prognostic classification systems can aide in defining favorable versus poor prognosis patients to help guide subsequent treatment. These systems include the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) and the disease-specific graded prognostic assessment (GPA). The use of these systems specifically in breast cancer patients is covered below. A general discussion of these classification systems is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Prognostic classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RPA is based on performance status, age, primary tumor site, and the presence of extracranial metastases (",
"      <a class=\"graphic graphic_table graphicRef77561 \" href=\"UTD.htm?7/63/8187\">",
"       table 1",
"      </a>",
"      ). It was validated in 117 breast cancer patients who were treated with WBRT [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/53\">",
"       53",
"      </a>",
"      ]. Only two patients met criteria for RPA Class I, leaving roughly 50 percent of patients in each of RPA Class II and III. RPA Class II patients had a longer median survival compared to those with RPA Class III (8 versus 3 months, respectively).",
"     </li>",
"     <li>",
"      Recent studies have indicated that prognostic factors for patients with brain metastases vary by primary histology [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The breast cancer specific GPA (",
"      <a class=\"graphic graphic_table graphicRef54755 \" href=\"UTD.htm?11/45/11996\">",
"       table 6",
"      </a>",
"      ) takes into account Karnofsky performance status, age, and breast cancer subtype (defined by ER, PR, and HER2-status) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/54\">",
"       54",
"      </a>",
"      ]. Median survival time by GPA score was as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0-1.0 &mdash; 3 months (range, 3 to 4 months)",
"     </li>",
"     <li>",
"      1.5-2.0 &mdash; 8 months (range, 6 to 9 months)",
"     </li>",
"     <li>",
"      2.5-3.0 &mdash; 15 months (range, 13 to 16 months)",
"     </li>",
"     <li>",
"      3.5-4.0 &mdash; 25 months (range, 23 to 27 months)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H328010014\">",
"    <span class=\"h1\">",
"     LEPTOMENINGEAL METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite improvements in the prognosis of some patients with parenchymal brain metastases from breast cancer, the prognosis of patients with leptomeningeal metastases (LM, otherwise called carcinomatous meningitis) has not markedly changed in the last decade. As an example, a retrospective series of 68 women with metastatic breast cancer who had evidence of LM, median overall survival was four months and the one-year survival rate was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19464/abstract/55\">",
"     55",
"    </a>",
"    ]. On multivariate analysis, independent factors associated with survival were: conversion to negative cytology (hazard ratio [HR] for death 0.42, 95% CI 0.20-0.89), absence of systemic metastases (ie, metastasis limited to LM with or without brain metastases, HR 0.42, 95% CI 0.19-0.91), and combined modality treatment (HR 0.24, 95% CI 0.09-0.63). The general treatment of leptomeningeal metastases is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of brain metastases remains a significant clinical challenge in patients with breast cancer.",
"     </li>",
"     <li>",
"      In general, patients with stable or controlled extracranial disease and patients with human epidermal growth factor receptor 2 (HER2)-positive or estrogen receptor (ER)-positive disease appear to have a prolonged survival, and more aggressive approaches may be undertaken in such patients.",
"     </li>",
"     <li>",
"      Symptom management of brain metastases includes control of peritumoral edema and increased intracranial pressure with corticosteroids, treatment of seizures, and management and prevention of venous thromboembolic disease. (See",
"      <a class=\"local\" href=\"#H22654193\">",
"       'Primary management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a single central nervous system (CNS) lesion that is surgically accessible, we recommend surgical resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Stereotactic radiosurgery (SRS) is an option for patients with lesions in surgically inaccessible locations and those who are not surgical candidates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with more than one metastasis, but a limited number (generally two to three lesions), treatment is individualized, based upon such factors as tumor size and location, tumor biology, and anticipated treatment toxicity. We generally prefer whole brain radiation therapy (WBRT) followed by SRS due to the risk of intracranial relapse in the absence of WBRT. Other options include surgical resection, often followed by WBRT or SRS, and SRS alone. Since WBRT has not demonstrated an overall survival benefit in this setting, a discussion of the risks and benefits is appropriate and educated patients may choose to forego routine WBRT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with multiple metastases, we recommend WBRT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). SRS may be added after WBRT in patients with good prognosis and a limited number of residual lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with brain metastases and a poor prognosis (poor performance status or rapidly progressive systemic disease), we recommend WBRT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link\">",
"       \"Treatment of brain metastases in poor prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with recurrent brain metastases after WBRT, stereotactic radiosurgery (SRS) may be an option, particularly in patients with a limited volume of disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment of recurrent/progressive metastases'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of brain metastases in poor prognosis patients\", section on 'Recurrent brain metastases'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with newly diagnosed brain metastases from HER2-positive breast cancer,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/23/9592?source=see_link\">",
"       lapatinib",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is an alternative option to WBRT, assuming close follow up and an understanding of the limitations of the existing data. (See",
"      <a class=\"local\" href=\"#H18843855\">",
"       'HER2-positive metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/1\">",
"      Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/2\">",
"      Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 2012; 136:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/3\">",
"      Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/4\">",
"      Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/5\">",
"      Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/6\">",
"      Yerushalmi R, Woods R, Kennecke H, et al. Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat 2010; 120:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/7\">",
"      Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/8\">",
"      Park YH, Park MJ, Ji SH, et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009; 100:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/9\">",
"      Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/10\">",
"      Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/11\">",
"      Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol 2005; 23:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/12\">",
"      Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/13\">",
"      Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/14\">",
"      Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/15\">",
"      Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/16\">",
"      Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008; 13:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/17\">",
"      Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/18\">",
"      Dawood S, Lei X, Litton JK, et al. Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer 2012; 118:4652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/19\">",
"      Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/20\">",
"      Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011; 6:e21030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/21\">",
"      Pestalozzi BC, Holmes E, de Azambuja E, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 2013; 14:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/22\">",
"      Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/23\">",
"      Kelly PJ, Lin NU, Claus EB, et al. Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors. Cancer 2012; 118:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/24\">",
"      Stewart DJ, Dahrouge S. Response of brain metastases from breast cancer to megestrol acetate: a case report. J Neurooncol 1995; 24:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/25\">",
"      Salvati M, Cervoni L, Innocenzi G, Bardella L. Prolonged stabilization of multiple and single brain metastases from breast cancer with tamoxifen. Report of three cases. Tumori 1993; 79:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/26\">",
"      Madhup R, Kirti S, Bhatt ML, et al. Letrozole for brain and scalp metastases from breast cancer--a case report. Breast 2006; 15:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/27\">",
"      Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22:3608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/28\">",
"      Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992; 69:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/29\">",
"      Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/30\">",
"      Friedman HS, Evans B and Reardon DA. Phase II trial of temozolomide for patients with progressive brain metastases (abstract #408). Proc Am Soc Clin Oncol 2003; 22:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/31\">",
"      Siena S, Landonio G, Beaietta E. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (abstract #407). Proc Am Soc Clin Oncol 2003; 22:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/32\">",
"      Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/33\">",
"      Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/34\">",
"      Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/35\">",
"      Christodoulou C, Bafaloukos D, Linardou H, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/36\">",
"      Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/37\">",
"      Lin NU, Di&eacute;ras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452.",
"     </a>",
"    </li>",
"    <li>",
"     Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastses (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU) (abstract #1094). J Clin Oncol 2008; 26:1094.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/39\">",
"      Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/40\">",
"      Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255.",
"     </a>",
"    </li>",
"    <li>",
"     Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases file://clinicaltrials.gov/ct2/show/NCT01004172 (Accessed on May 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/42\">",
"      Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/43\">",
"      Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008; 26:5649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/44\">",
"      DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979; 44:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/45\">",
"      Mahmoud-Ahmed AS, Suh JH, Lee SY, et al. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002; 54:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/46\">",
"      Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 2008; 19:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/47\">",
"      Melisko ME, Moore DH, Sneed PK, et al. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008; 88:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/48\">",
"      Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/49\">",
"      Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/50\">",
"      Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/51\">",
"      Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/52\">",
"      Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008; 10:R20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/53\">",
"      Le Scodan R, Massard C, Mouret-Fourme E, et al. Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys 2007; 69:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/54\">",
"      Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19464/abstract/55\">",
"      Lee S, Ahn HK, Park YH, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 2011; 129:809.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 775 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-3CA5444EA1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19464=[""].join("\n");
var outline_f19_0_19464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22654193\">",
"      PRIMARY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18843855\">",
"      HER2-positive metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF RECURRENT/PROGRESSIVE METASTASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H539835705\">",
"      Stereotactic radiosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cytotoxic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Targeted agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18843777\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18843770\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H328010061\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328009664\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H328010014\">",
"      LEPTOMENINGEAL METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/63/8187\" title=\"table 1\">",
"      Brain mets prognosis RTOG RPA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/29/3549\" title=\"table 2\">",
"      Performance status measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/6/9326\" title=\"table 3\">",
"      Studies of systemic therapy for brain metastases breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/8/38028\" title=\"table 4\">",
"      Prog brain mets HER2-pos BC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/3/34875\" title=\"table 5\">",
"      Prog brain mets trip-neg BC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/45/11996\" title=\"table 6\">",
"      Graded prognostic assessment for brain metastases breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39335?source=related_link\">",
"      Management of vasogenic edema in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36486?source=related_link\">",
"      Treatment of brain metastases in poor prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_0_19465="Causes of dilated cardiomyopathy";
var content_f19_0_19465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of dilated cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19465/contributors\">",
"     Marilyn Weigner, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19465/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19465/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19465/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/0/19465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy (DCM) is characterized by dilation and impaired contraction of one or both ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Affected patients have impaired systolic function and may or may not develop overt heart failure (HF). The presenting manifestations can include atrial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular arrhythmias, and sudden death can occur at any stage of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dilated cardiomyopathy is currently responsible for approximately 10,000 deaths and 46,000 hospitalizations each year in the United States. Furthermore, idiopathic DCM is the primary indication for cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition, clinical presentation, and causes of DCM will be reviewed here. The initial evaluation of the patient with suspected HF and the subsequent evaluation to determine the cause are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of DCM requires evidence of dilatation and impaired contraction of the left ventricle or both ventricles (eg, left ventricular ejection fraction &lt;40 percent or fractional shortening less than 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The disease is considered idiopathic if primary and secondary causes of heart disease (eg, myocarditis and coronary artery disease) are excluded by evaluation including history and physical examination, laboratory testing, coronary angiography (to exclude &gt;50 percent obstruction of one or more coronary arteries), echocardiography, and, endomyocardial biopsy when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present between the ages of 20 and 60, but DCM can occur in children and older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/3\">",
"     3",
"    </a>",
"    ]. Affected patients can present in a number of different ways [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Symptoms of HF &mdash; progressive dyspnea with exertion, impaired exercise capacity, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema &mdash; are most common. Other presentations include the incidental detection of asymptomatic cardiomegaly and symptoms related to coexisting arrhythmia, conduction disturbance, thromboembolic complications, or sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation of the patient with suspected heart failure\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical course is largely unpredictable in the individual patient and may depend in part upon the cause of the heart disease. There are also disease-independent predictors of survival, the most important of which are New York Heart Association functional class, left ventricular ejection fraction, and maximal oxygen consumption (peak VO2). These prognostic determinants assume that the cause of the myocardial dysfunction cannot be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy can be caused by a variety of disorders (",
"    <a class=\"graphic graphic_table graphicRef60494 \" href=\"UTD.htm?4/53/4958\">",
"     table 1",
"    </a>",
"    ). These conditions will be briefly reviewed here; many are discussed in detail elsewhere. In many cases, however, no etiology can be found and the cardiomyopathy is deemed idiopathic.",
"   </p>",
"   <p>",
"    The relative frequency of the different causes in patients with initially unexplained cardiomyopathy was assessed in a review of 1230 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Idiopathic &mdash; 50 percent",
"     </li>",
"     <li>",
"      Myocarditis &mdash; 9 percent",
"     </li>",
"     <li>",
"      Ischemic heart disease &mdash; 7 percent",
"     </li>",
"     <li>",
"      Infiltrative disease &mdash; 5 percent",
"     </li>",
"     <li>",
"      Peripartum cardiomyopathy &mdash; 4 percent",
"     </li>",
"     <li>",
"      Hypertension &mdash; 4 percent",
"     </li>",
"     <li>",
"      HIV infection &mdash; 4 percent",
"     </li>",
"     <li>",
"      Connective tissue disease &mdash; 3 percent",
"     </li>",
"     <li>",
"      Substance abuse &mdash; 3 percent",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       Doxorubicin",
"      </a>",
"      &mdash; 1 percent",
"     </li>",
"     <li>",
"      Other &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of cardiomyopathy have sometimes been divided into reversible and irreversible disorders. However, this distinction is somewhat arbitrary since many of these conditions can be either reversible or nonreversible (eg, ischemic cardiomyopathy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary atherosclerosis is the most common cause of heart failure in the United States, comprising 50 to 75 percent of patients with HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .) Although the term &ldquo;ischemic cardiomyopathy&rdquo; has been used to describe ischemic myocardial dysfunction (particularly in North America), this term is not supported by the 2006 American Heart Association or 2007 European Society of Cardiology cardiomyopathy classification systems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with ischemic cardiomyopathy have known coronary heart disease. However, occult disease is a not uncommon cause of DCM, accounting for as many as 7 percent of otherwise unexplained cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/8\">",
"     8",
"    </a>",
"    ]. These observations plus the potential reversibility of hibernating myocardium (",
"    <a class=\"graphic graphic_figure graphicRef55621 \" href=\"UTD.htm?10/24/10638\">",
"     figure 1",
"    </a>",
"    ) constitute the rationale for performing angiography in most patients with HF of uncertain etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the detection of hibernating myocardium and the management of such patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stress-induced cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An uncommon but increasingly reported cause of an acute, usually ST elevation coronary syndrome occurring in the absence of critical coronary artery disease is stress-induced cardiomyopathy, also called transient left ventricular apical ballooning, takotsubo cardiomyopathy, and broken heart syndrome. This disorder is typically precipitated by intense psychologic stress and primarily occurs in postmenopausal women. The characteristic finding of apical ballooning is seen on left ventriculography or echocardiography. Despite frequent hemodynamic compromise or even cardiogenic shock, almost all patients recover completely within one to four weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Infectious cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of infectious organisms can lead to myocarditis and DCM (",
"    <a class=\"graphic graphic_table graphicRef56995 \" href=\"UTD.htm?35/10/36014\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Viral cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infection is the most common cause of myocarditis and has been implicated in the development of DCM. Viruses known to involve the myocardium include parvovirus B19, human herpesvirus 6, coxsackievirus, influenza virus, adenovirus, echovirus, cytomegalovirus, and human immunodeficiency virus (HIV). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial immune response limits the degree of viremia early during infection and protects against myocarditis. If, however, this response is insufficient, the virus may not be eliminated and myocyte injury may ensue via one or both of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct cytotoxicity via receptor-mediated entry of the virus into cardiac myocytes",
"     </li>",
"     <li>",
"      An adverse autoimmune response induced by persisting viral genomic fragments that may not be capable of replicating as intact virus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other aspects of viral myocarditis, including clinical manifestations, diagnosis, and therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link\">",
"     \"Natural history and therapy of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart disease associated with HIV infection is being recognized with increasing frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The proposed mechanisms of cardiac damage include drug toxicity, secondary infection, myocardial damage by HIV itself, and an autoimmune process induced by HIV itself or in association with other cardiotropic viruses such as coxsackievirus, cytomegalovirus, or Epstein-Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link\">",
"     \"Cardiac involvement in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A direct role for HIV infection in the development of cardiomyopathy was suggested by a study of 952 asymptomatic HIV-positive patients who were followed for 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/10\">",
"     10",
"    </a>",
"    ]. Dilated cardiomyopathy was diagnosed on echocardiography in 8 percent, most of whom had evidence of a myocarditis on biopsy. Among these patients, 76 percent had HIV nucleic acid sequences present in myocytes, while 26 percent also had evidence of coxsackievirus, cytomegalovirus, or Epstein-Barr virus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Chagas disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease, which is a protozoan infection due to Trypanosoma cruzi, is the leading cause of DCM in Central and South America. It is characterized clinically by an acute myocarditis, cardiac enlargement, tachycardia, and nonspecific ECG abnormalities including right bundle branch block and premature ventricular contractions. Patients can develop left ventricular apical aneurysms that are pathognomonic for this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement with Lyme disease is usually manifested as a conduction abnormality. Cardiac muscle dysfunction can also occur; it is often self-limited and mild, leading to transient cardiomegaly or pericardial effusion on echocardiogram or chest x-ray. However, occasional patients develop symptomatic myocarditis and DCM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=see_link\">",
"     \"Lyme carditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Genetic causes of dilated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with idiopathic DCM, it is estimated that up to 50 percent have familial disease. No clinical or histologic criteria, other than family history and careful examination of relatives (including those who are asymptomatic), have been derived to distinguish familial from nonfamilial disease. The mode of inheritance is usually autosomal dominant, although autosomal recessive, X-linked, and mitochondrial inheritance have also been described. These disorders, as well as recommendations for screening and counseling family members, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=see_link\">",
"     \"Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibodies to a variety of cardiac proteins are present in approximately 30 percent of patients with DCM. These antibodies are also present in 20 to 30 percent of the first and second degree relatives of DCM patients, compared to 1 to 2 percent of control subjects. Furthermore, among relatives of DCM patients the presence of such antibodies is associated with a greater likelihood of developing DCM. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Autoimmunity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Dilated cardiomyopathies in patients who do not have a known family history of disease may also have a genetic basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link&amp;anchor=H22#H22\">",
"     \"Genetics of dilated cardiomyopathy\", section on 'Sporadic dilated cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Inherited syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilated cardiomyopathy can be a common and important component of a number of inherited disorders, including a number of neuromuscular diseases (eg, muscular dystrophies, and myotonic dystrophy), hereditary hemochromatosis, and the hereditary sideroblastic anemias and thalassemias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small proportion of patients with HCM who survive the early risk of sudden death develop progressive myocardial wall thinning, a reduction in systolic performance, and an increase in left ventricular dimensions in the long term, resembling the morphologic and functional features of dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'End-stage HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Left ventricular noncompaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular noncompaction (LVNC), also called isolated ventricular noncompaction and left ventricular hypertrabeculation, is a rare unclassified cardiomyopathy with an altered myocardial wall due to intrauterine arrest of compaction of the loose interwoven meshwork that makes up the fetal myocardial primordium. LVNC has been identified in 0.05 percent of patients undergoing echocardiography. Affected patients present with heart failure, thromboembolism, or ventricular arrhythmias. The diagnosis is established by echocardiography, although the changes can also be seen on MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=see_link\">",
"     \"Isolated left ventricular noncompaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392006\">",
"    <span class=\"h2\">",
"     Toxic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;DCM can be a direct result of toxic exposure from a variety of agents, most notably alcohol, cocaine, medications, particularly chemotherapeutic drugs, and radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392013\">",
"    <span class=\"h3\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive alcohol consumption can lead to myocardial dysfunction, although the pathogenesis and factors that determine patient susceptibility are still poorly understood. Alcohol is believed to be toxic to cardiac myocytes via oxygen free radical damage and defects in cardiac protein synthesis.",
"   </p>",
"   <p>",
"    The risk of developing alcoholic DCM is related to both mean daily alcohol intake and the duration of drinking. However, individual susceptibility remains important. The typical findings in patients with alcoholic DCM are left ventricular dilatation with reduced ejection fraction. More advanced cases have biventricular failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link\">",
"     \"Alcoholic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abstinence can lead to a dramatic improvement in cardiac function if the disease is diagnosed early. Thus, careful questioning for a history of alcohol use is an important part of the evaluation of a patient with DCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392194\">",
"    <span class=\"h4\">",
"     Distinction from cirrhotic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While alcoholic cardiomyopathy is one cause of heart disease in patients with cirrhosis, experimental and observational studies have found that cirrhosis is associated with myocardial dysfunction independent of alcohol exposure. The causes and manifestations of cirrhotic cardiomyopathy are not well defined. The condition has been defined as otherwise unexplained chronic cardiac dysfunction in patients with cirrhosis with impaired contractile responsiveness to stress",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction with associated electrophysiologic abnormalities. The left atrium may be dilated but the left ventricular cavity size is generally normal, although dilatation may develop in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Unclassified cardiomyopathies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392020\">",
"    <span class=\"h3\">",
"     Cocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cocaine is associated with cardiomyopathy, but the relationship is less well understood than that between cocaine and coronary ischemia. Nevertheless, cardiomegaly with otherwise unexplained heart failure in a young person should raise the possibility of cocaine abuse. Possible mechanisms include a direct toxic effect, the cocaine-induced hyperadrenergic state, and, in parenteral cocaine abusers, an infectious cardiomyopathy. Abstinence usually leads to complete reversal of the myocardial dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392027\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medications are associated with cardiomyopathy and discontinuation of the implicated drug may result in significant improvement (",
"    <a class=\"graphic graphic_table graphicRef60494 \" href=\"UTD.htm?4/53/4958\">",
"     table 1",
"    </a>",
"    ). Anthracycline-induced cardiomyopathy has been the most extensively studied. Another chemotherapeutic agent associated with frequent cardiotoxicity is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , particularly in patients also treated with an anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    is a monoclonal antibody directed against the c-erbB-2",
"    <span class=\"nowrap\">",
"     (HER2/neu)",
"    </span>",
"    receptor that is used in the treatment of breast cancer. There is biologic plausibility for cardiac toxicity, since HER2 signaling appears to play an important role in cardiac development and cardioprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/13\">",
"     13",
"    </a>",
"    ]. Direct evidence of such an effect was provided in a study of mice with ventricular restricted deletion of the HER2 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/14\">",
"     14",
"    </a>",
"    ]. These mice developed multiple signs of a cardiomyopathy. In addition, cardiomyocytes from these mice showed enhanced susceptibility to anthracycline toxicity. Cardiomyopathy also develops after a loss of function mutation in HER2 in ventricular myocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2392034\">",
"    <span class=\"h3\">",
"     Trace elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trace elements are known to have an important role in myocardial metabolism and their accumulation (cobalt, arsenic) or deficiency (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    ) can be responsible for a form of DCM that is indistinguishable from an idiopathic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H48#H48\">",
"     \"Overview of dietary trace minerals\", section on 'Selenium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of trace elements was assessed in a study in which myocardial and skeletal muscle biopsies were obtained from 13 patients with an idiopathic DCM, 35 patients with valvular or ischemic heart disease, and 4 normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared to normals, patients with a DCM had a significant increase in myocardial concentration of mercury (22,000 times normal), antimony (12,000 fold higher), gold (increased 11 fold), chromium (13 fold higher), and cobalt (4 times higher). In comparison, patients with valvular or ischemic heart disease had myocardial concentrations of trace elements that were &le;5 times greater than normal. Skeletal muscle concentrations of trace elements were normal in all groups of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Peripartum cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum cardiomyopathy is a rare cause of DCM of unclear etiology that occurs in late pregnancy and the early postpartum period. The diagnosis requires exclusion of other causes of cardiomyopathy. A variety of definitions have been proposed for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/17\">",
"     17",
"    </a>",
"    ]. This condition is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tachycardia-mediated cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cardiomyopathy has been reported in patients with chronic supraventricular tachycardias including atrial fibrillation, atrioventricular nodal reentry, and preexcitation syndromes with ventricular rates of 130 to 200",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The rate of the tachycardia appears to correlate with the degree of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of myocardial dysfunction in this setting is not clear. Among the changes that have been observed are a reduction in myocyte contractility, abnormalities in myocardial architecture, and a decrease in calcium responsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Left ventricular dysfunction can occur without dilatation. Definitive treatment of the arrhythmia results in complete reversal of the myocardial dysfunction (generally within three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of cardiac sarcoidosis depend upon the location and extent of granulomatous inflammation. In addition to a reversible form of DCM, other cardiac manifestations include conduction abnormalities, ventricular and supraventricular arrhythmias, pericarditis, and valvular dysfunction due to papillary muscle involvement. Cardiac involvement may precede, follow, or occur concurrently with involvement of the lungs or other organs. Antecedent pulmonary or other organ involvement may be absent or not apparent and presentation may be limited to cardiac abnormalities. An acute cardiac presentation may resemble hypertrophic cardiomyopathy with asymmetric, which is caused by edema rather than myocyte hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"     \"Cardiac sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should consider the possibility of sarcoid heart disease when confronted with an otherwise healthy young or middle-aged person with cardiac symptoms or a patient with known sarcoidosis who develops arrhythmias, conduction disease, or HF. Diagnosis depends upon recognition of the multisystem features of sarcoidosis and securing the evidence of noncaseating granuloma either in the myocardium or in other affected tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with end-stage renal disease being treated with hemodialysis can develop a dilated cardiomyopathy via an uncertain mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmunity may be a cause of DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/26\">",
"     26",
"    </a>",
"    ], and the presence of autoantibodies may identify family members of patients with DCM who are at a greater risk of developing cardiomyopathy. Autoimmunity has also been implicated in the pathogenesis of myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H22#H22\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Autoimmune mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of cardiac autoantibodies have been identified. These antibodies target a variety of antigens, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beta-1 adrenoceptor",
"     </li>",
"     <li>",
"      Alpha-myosin heavy chain",
"     </li>",
"     <li>",
"      Beta-myosin heavy chain",
"     </li>",
"     <li>",
"      Myosin light chain",
"     </li>",
"     <li>",
"      Troponin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Collectively, these autoantibodies are sometimes referred to as anti-heart antibodies (AHAs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Evidence of pathogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a rabbit model, immunization with sequences of the beta-1 adrenoreceptor induced the production of beta-1 adrenoceptor autoantibodies and resulted in anatomic and histologic changes in the myocardium resembling those seen in human DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/27\">",
"     27",
"    </a>",
"    ]. A similar study in rats also demonstrated the production of autoantibodies as well as severe left ventricular dilatation and dysfunction in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/28\">",
"     28",
"    </a>",
"    ]. These findings appear to be applicable to humans since these autoantibodies can be detected in as many as 38 percent of patients with an idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for a pathogenetic role of beta-1 adrenoceptor autoantibodies comes from the efficacy of eliminating them by immunoadsorption. In one report, immunoadsorption completely eliminated the beta-1 adrenoceptor autoantibodies in the 17 patients undergoing this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/30\">",
"     30",
"    </a>",
"    ]. After one year, the mean left ventricular ejection fraction increased from 22 to 38 percent, left ventricular end-diastolic volume decreased by 15 percent, and the autoantibodies did not reappear. In contrast, there were no changes in antibody levels or left ventricular function in 17 patients with these antibodies who received only standard medical therapy.",
"   </p>",
"   <p>",
"    Similar improvement in left ventricular ejection fraction was noted in a later report of eight patients with DCM and beta-1 adrenoceptor antibodies treated with selective immunoadsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/31\">",
"     31",
"    </a>",
"    ]. The advantage of selective immunoadsorption is that immunoglobulin replacement is not required.",
"   </p>",
"   <p>",
"    A potential pathogenic mechanism for beta-1 adrenoceptor autoantibodies was demonstrated in a study of murine DCM induced by beta-1 adrenoceptor autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/32\">",
"     32",
"    </a>",
"    ]. The autoantibodies acted as agonists, shifting endogenous beta-1 adrenoceptors into the agonist-coupled high-affinity state, thereby triggering an intracellular protein kinase A-dependent signaling cascade in cardiomyocytes. Sustained activation caused intracellular calcium mishandling, cardiomyocyte apoptosis, and HF with DCM.",
"   </p>",
"   <p>",
"    In addition to a role in some cases of DCM, beta-1 adrenoceptor autoantibodies have also been linked to myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H24#H24\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Anti-beta-1 adrenoceptor antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;AHAs are found in approximately 30 percent of DCM patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/29,30,33\">",
"     29,30,33",
"    </a>",
"    ], and in 20 to 30 percent of their asymptomatic relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/34\">",
"     34",
"    </a>",
"    ]. The significance of AHAs in the healthy relatives of patients with DCM was evaluated in a series of 169 probands and 592 of their first and second degree relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/35\">",
"     35",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AHAs were significantly more common in family members of DCM patients than in patients with noninflammatory heart disease, patients ischemic heart disease, or normal blood donors (32 versus 1, 1, and 2.5 percent, respectively).",
"     </li>",
"     <li>",
"      Relatives of DCM patients who later developed DCM were more likely to have AHAs than were relatives who did not progress (69 versus 37 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, AHAs were more common in family members of DCM patients than in control subjects, and the presence of AHAs in asymptomatic family members was associated with an increased likelihood of developing disease. However, fully defining the role of autoimmune factors in familial cardiomyopathy requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2391823\">",
"    <span class=\"h3\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac disease is common in systemic lupus erythematosus. Affected patients can develop valvular, pericardial, or coronary disease or myocarditis. Patients with myocardial involvement can present with resting tachycardia disproportionate to body temperature, electrocardiographic abnormalities (such as ST-T wave abnormalities), and unexplained cardiomegaly. Immunosuppressive therapy does not always lead to improved myocardial function in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link\">",
"     \"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2391874\">",
"    <span class=\"h3\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reports from Italy suggest that celiac disease, which is often clinically unsuspected, accounts for as many as 5 percent of patients with autoimmune myocarditis or idiopathic DCM [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In one report of nine such patients, none had classic gastrointestinal symptoms of celiac disease (recurrent abdominal pain, diarrhea, and weight loss), but all had iron deficiency anemia refractory to iron replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/36\">",
"     36",
"    </a>",
"    ]. Cardiac function improved following a gluten-free diet with or without immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these findings are intriguing, it is premature to screen all patients with otherwise unexplained cardiomyopathy for celiac disease. However, it is reasonable to question for a history of gastrointestinal complaints or refractory iron deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Endocrine dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction, excess sympathetic activity in pheochromocytoma, and rarely Cushing's syndrome and growth hormone (GH) excess or deficiency can cause cardiac dysfunction which can usually be reversed by correction of the endocrine disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The exact mechanisms by which hyperthyroidism or hypothyroidism can lead to DCM are not known. Thyroid hormone is known to alter preload, afterload, heart rate, and contractility, each of which may contribute to cardiac dysfunction. There is also some evidence in experimental animals that excess T3 causes myocyte hypertrophy and changes in specific protein synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"       \"Cardiovascular effects of hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"       \"Cardiovascular effects of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excess sympathomimetic amines in pheochromocytoma can cause focal direct myocyte injury followed by inflammation, downregulation of beta receptors, and a net reduction of viable myofibrils [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As many as 10 percent of patients with newly diagnosed acromegaly have HF, usually with a high cardiac output [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most of the biologically active effects of GH on the heart appear to be mediated via local production of insulin-like growth factor I (IGF-I), which in turn regulates tissue growth by paracrine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      autocrine mechanisms. In an analysis from the Framingham Heart Study, patients with serum IGF-I concentrations below the median (&lt;140",
"      <span class=\"nowrap\">",
"       microg/L)",
"      </span>",
"      were found to have an increased likelihood of developing HF at five years (10.2 versus 5.3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=see_link&amp;anchor=H5#H5\">",
"       \"Unproven therapies for chronic systolic heart failure\", section on 'Growth hormone'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Nutritional deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies in thiamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    have been reported to produce HF and replacement therapy results in improvement in cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/7,43\">",
"     7,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thiamine plays an important role in normal oxidative phosphorylation and therefore myocardial energy production. Thiamine deficiency initially presents as a high output state secondary to vasodilation; this is followed by eventual depression of myocardial function and the development of a low output state [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"       Selenium",
"      </a>",
"      deficiency decreases the activity of glutathione peroxide, resulting in increased free radicals that are toxic to cardiac myocytes. The development of Keshan disease, an endemic cardiomyopathy that affects children and women of childbearing age in areas of China, has been linked to Se deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/44\">",
"       44",
"      </a>",
"      ]. The geographical distribution of Keshan disease is associated with local diets, which are nearly devoid of Se. An animal model of Keshan disease in Se deficient mice infected with Coxsackievirus has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/45\">",
"       45",
"      </a>",
"      ]. The mice have increased mutations in the viral genome, leading to a virus with greater cardiac virulence, causing a cardiomyopathy similar to that seen in Keshan disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link&amp;anchor=H48#H48\">",
"       \"Overview of dietary trace minerals\", section on 'Selenium'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       Carnitine",
"      </a>",
"      deficiency impairs the oxidation of fatty acids, resulting in lipid accumulation in the myocyte cytoplasm. This problem is reversed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      replacement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"       \"Carnitine metabolism in renal disease and dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances, including obstructive and nonobstructive sleep apnea, can contribute to the impairment of left ventricular dysfunction. A history of snoring, daytime somnolence, and obesity should alert the clinician to the diagnosis. Effective therapy, as with nasal continuous positive airway pressure during sleep, can lead to a significant improvement in left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19465/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       \"Patient information: Dilated cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2391772\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilated cardiomyopathy (DCM) is characterized by dilatation and impaired contraction of one or both ventricles.",
"     </li>",
"     <li>",
"      DCM is caused by a variety of disorders although frequently no etiology can be found and the cardiomyopathy is deemed idiopathic. Cardiac evaluation of family members has revealed that up to 50 percent of patients diagnosed with idiopathic cardiomyopathy have a familial DCM.",
"     </li>",
"     <li>",
"      Current major society classification systems for cardiomyopathy exclude heart disease secondary to coronary artery disease, valvular, or congenital heart disease. However, in clinical practice, the term &ldquo;ischemic cardiomyopathy&rdquo; is frequently used to describe ischemic myocardial dysfunction.",
"     </li>",
"     <li>",
"      Although most patients with ischemic cardiomyopathy have known coronary disease, in some, the presence of severe coronary artery disease is not detected until coronary angiography is performed as part of an evaluation to identify a cause for myocardial dysfunction.",
"     </li>",
"     <li>",
"      Causes of DCM include stress-induced, infectious, toxic, genetic, peripartum, tachycardia-mediated, sarcoidosis, end-stage renal disease, autoimmune disease, endocrine dysfunction, and nutritional deficiencies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/1\">",
"      Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/2\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/3\">",
"      Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/4\">",
"      Luk A, Ahn E, Soor GS, Butany J. Dilated cardiomyopathy: a review. J Clin Pathol 2009; 62:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/5\">",
"      Elliott P. Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart 2000; 84:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/6\">",
"      Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Am J Cardiol 1992; 69:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/7\">",
"      Abelmann WH, Lorell BH. The challenge of cardiomyopathy. J Am Coll Cardiol 1989; 13:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/8\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/9\">",
"      Cohen IS, Anderson DW, Virmani R, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 1986; 315:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/10\">",
"      Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 1998; 339:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/11\">",
"      Lipshultz SE, Easley KA, Orav EJ, et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998; 97:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/12\">",
"      Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005; 46:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/13\">",
"      Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/14\">",
"      Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/15\">",
"      Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99:8880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/16\">",
"      Frustaci A, Magnavita N, Chimenti C, et al. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol 1999; 33:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/17\">",
"      Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/18\">",
"      Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/19\">",
"      Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J 1993; 126:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/20\">",
"      Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/21\">",
"      Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/22\">",
"      Fishberger SB, Colan SD, Saul JP, et al. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol 1996; 19:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/23\">",
"      Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268:H836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/24\">",
"      Perreault CL, Shannon RP, Komamura K, et al. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Invest 1992; 89:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/25\">",
"      Aoki J, Ikari Y, Nakajima H, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int 2005; 67:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/26\">",
"      Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009; 73:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/27\">",
"      Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/28\">",
"      Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/29\">",
"      Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/30\">",
"      M&uuml;ller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/31\">",
"      Wallukat G, M&uuml;ller J, Hetzer R. Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 2002; 347:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/32\">",
"      Jane-wit D, Altuntas CZ, Johnson JM, et al. Beta 1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007; 116:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/33\">",
"      Caforio AL, Keeling PJ, Zachara E, et al. Evidence from family studies for autoimmunity in dilated cardiomyopathy. Lancet 1994; 344:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/34\">",
"      Caforio AL, Bonifacio E, Stewart JT, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol 1990; 15:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/35\">",
"      Caforio AL, Mahon NG, Baig MK, et al. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation 2007; 115:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/36\">",
"      Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/37\">",
"      Curione M, Barbato M, De Biase L, et al. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. Lancet 1999; 354:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/38\">",
"      Kantharia BK, Richards HB, Battaglia J. Reversible dilated cardiomyopathy: an unusual case of thyrotoxicosis. Am Heart J 1995; 129:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/39\">",
"      Sardesai SH, Mourant AJ, Sivathandon Y, et al. Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure. Br Heart J 1990; 63:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/40\">",
"      Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002; 112:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/41\">",
"      Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/42\">",
"      Vasan RS, Sullivan LM, D'Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 2003; 139:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/43\">",
"      Abelmann, WH. Cardiomyopathies and inflammatory disorders. Curr Opin Cardiol 1992; 7:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/44\">",
"      Observations on effect of sodium selenite in prevention of Keshan disease. Chin Med J (Engl) 1979; 92:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/45\">",
"      Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med 1995; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19465/abstract/46\">",
"      Malone S, Liu PP, Holloway R, et al. Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure. Lancet 1991; 338:1480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3516 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19465=[""].join("\n");
var outline_f19_0_19465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2391772\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stress-induced cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Infectious cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Viral cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Genetic causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Inherited syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2392006\">",
"      Toxic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2392013\">",
"      - Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2392194\">",
"      Distinction from cirrhotic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2392020\">",
"      - Cocaine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2392027\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2392034\">",
"      - Trace elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Evidence of pathogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Familial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2391823\">",
"      - Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2391874\">",
"      - Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Endocrine dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Nutritional deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2391772\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3516|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10638\" title=\"figure 1\">",
"      Revasc hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/53/4958\" title=\"table 1\">",
"      Causes dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/10/36014\" title=\"table 2\">",
"      Causes of myocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/59/5047?source=related_link\">",
"      Familial dilated cardiomyopathy: Prevalence, diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40759?source=related_link\">",
"      Lyme carditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=related_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39221?source=related_link\">",
"      Unproven therapies for chronic systolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_0_19466="Unusual causes of peptic ulcer disease";
var content_f19_0_19466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unusual causes of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/0/19466/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/0/19466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) and nonsteroidal antiinflammatory drugs (NSAIDs) account for the large majority of cases of peptic ulcer disease (PUD) in Europe, Asia, Australia, and some populations in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, several studies in the United States have demonstrated rates of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection of less than 75 percent in patients with duodenal ulcer not associated with use of NSAIDs. Studies from Rochester, New York, for example, found that after excluding NSAID use, 61 percent of duodenal ulcers (DU) and 63 percent of gastric ulcers (GU) were",
"    <em>",
"     H. pylori",
"    </em>",
"    positive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/1\">",
"     1",
"    </a>",
"    ]. Only 52 percent of whites with DU were",
"    <em>",
"     H. pylori",
"    </em>",
"    positive, compared with 85 percent of nonwhites, underscoring the importance of demographics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before focusing on other etiologies of PUD, it is important to carefully exclude",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and NSAID use (",
"    <a class=\"graphic graphic_table graphicRef75002 \" href=\"UTD.htm?11/34/11820\">",
"     table 1",
"    </a>",
"    ). False negative",
"    <em>",
"     H. pylori",
"    </em>",
"    testing is commonly encountered, particularly for serology and for tests that depend upon the number of organisms (rapid urease testing on gastric mucosal biopsies, urease breath testing, histology, and stool antigen) when the patient has recently taken antibiotics, proton pump inhibitors, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    . Several lines of evidence indicate that",
"    <em>",
"     H. pylori",
"    </em>",
"    is frequently missed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/2\">",
"     2",
"    </a>",
"    ]. For example, serology is positive in some ulcer patients when other tests are negative; although some of these results may be false positives, some are due to suppression of organisms or isolated duodenal colonization, as considered below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .) Furthermore, about one-half of patients with aggressive ulcer disease attributable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    deny taking aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/3\">",
"     3",
"    </a>",
"    ]. Aspirin use has been detected in such patients by serum salicylate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are a number of less common, defined causes of PUD that are responsible for many of the remaining cases. In addition, some diseases, such as chronic obstructive pulmonary disease and cirrhosis, have been associated with a higher incidence of PUD than is seen in the normal population (",
"    <a class=\"graphic graphic_table graphicRef79691 \" href=\"UTD.htm?4/40/4749\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These causes are likely to take on increasing relative importance because of the rapid decline in",
"    <em>",
"     H. pylori",
"    </em>",
"    infection in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/2\">",
"     2",
"    </a>",
"    ], the availability of NSAIDs with lower risk of ulcer complications, and the use of concomitant therapies (such as proton pump inhibitors), which reduce the incidence of PUD in patients taking NSAIDs. The decrease in",
"    <em>",
"     H. pylori",
"    </em>",
"    prevalence is already translating into dramatic reductions in the prevalence of the two major associated diseases: peptic ulcer and gastric cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UNUSUAL CAUSES OF PEPTIC ULCER DISEASE AND UPPER GASTROINTESTINAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors and disorders have been implicated as causes of secondary peptic ulcer disease (PUD). A small proportion of acid hypersecretory and nonhypersecretory peptic ulcers remain at present in an idiopathic category; however, with careful evaluation (",
"    <a class=\"graphic graphic_table graphicRef75002 \" href=\"UTD.htm?11/34/11820\">",
"     table 1",
"    </a>",
"    ), this idiopathic category is very small. It is important to exclude malignancy as the cause of gastric and, rarely, duodenal ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Drugs other than NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of drugs that cause or exacerbate gastrointestinal (GI) bleeding, ulcer disease, or both, and the list is growing (",
"    <a class=\"graphic graphic_table graphicRef79691 \" href=\"UTD.htm?4/40/4749\">",
"     table 2",
"    </a>",
"    ). The role of nonsteroidal antiinflammatory drugs (NSAIDs) is well established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .) However, NSAIDs also appear to exacerbate the toxicity of several other drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Acetaminophen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in development of gastrointestinal complications (including bleeding and perforation) has been suggested in both population-based studies and a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. As a general rule, the risk was increased only in doses of 2 to 3 g per day or higher. The risk also appears to be increased with the combination of NSAIDs plus high dose acetaminophen compared with either alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship of bisphosphonates to clinically significant gastric ulcers is controversial. Damage and acute ulceration has been observed, but the proportion of patients who go on to clinically significant events appears limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The risk appears to be increased substantially with coadministration of NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H38#H38\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Gastrointestinal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although controversial over the years, the available evidence suggests that glucocorticoids alone are not associated with an increase in the risk for peptic ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, glucocorticoids exacerbate NSAID-induced ulceration. In a case-control study of 1415 patients, the combination of glucocorticoids and NSAIDs was associated with a fourfold increase in the risk for PUD compared to glucocorticoid users not receiving NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiplatelet agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is a significant risk factor for GI bleeding, particularly in patients with a prior risk of bleeding or on cotherapy with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAIDs. The risk may also be increased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    but data are limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H514073031#H514073031\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Bleeding risk and early CABG'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    has been associated with aggressive ulcer disease in patients undergoing transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/15\">",
"     15",
"    </a>",
"    ]. Sirolimus is known to inhibit wound healing and has been associated with small bowel ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, this connection is convincing and warrants cautious use of this agent in patients with a history of PUD and aggressive management of patients on the drug who develop symptoms or complications suggestive of PUD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Spironolactone",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two studies have implicated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    as a cause of upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In both studies, the risk of serious upper GI bleeding was increased nearly threefold among users of spironolactone. Furthermore, in one of the studies, the risk increased with high doses, suggesting dose-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk was also increased with advancing age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data regarding the impact of selective serotonin reuptake inhibitors (SSRIs) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    on the risk of upper gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. The risk of bleeding is higher when SSRIs are combined with NSAIDs or antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ), in patients with a history of peptic ulcer, and with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a population based cohort study, the use of SSRIs alone or in combination with NSAIDs was not associated with an increased 30-day mortality following a peptic ulcer bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one large nested case-control study, the risk was only apparent in non-users of acid inhibitors, suggesting that acid suppression attenuates the impact [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19092613\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain forms of chemotherapy have been associated with peptic disease. As an example, patients receiving continuous hepatic artery infusion of 5-fluorouracil frequently complain of abdominal pain. In one series, endoscopy usually revealed duodenal, gastric, or pyloric ulcerations and erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/28\">",
"     28",
"    </a>",
"    ]. The mechanisms have not been established; catheter migration with direct gastric infusion of chemotherapy did not explain most cases. These lesions responded to discontinuation of chemotherapy; H2 receptor blockers and proton pump inhibitors (PPIs) appeared to have little efficacy, but have not been formally tested. &nbsp;",
"   </p>",
"   <p>",
"    Some specific drugs used for chemotherapy may cause ulceration. One example is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    , a reversible tyrosine kinase inhibitor of the epidermal growth factor receptor used for cancer treatment. GI bleeding from peptic ulcers and ulcer perforation have been reported; not surprisingly, the risk appears greater when erlotinib is combined with NSAIDs, including cyclooxygenase (COX)-2 inhibitors, and in patients with a peptic ulcer history or treated with anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/29-32\">",
"     29-32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19092697\">",
"    <span class=\"h2\">",
"     Hormonal or mediator-induced, including secondary acid hypersecretory states",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gastrinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic tetrad of the Zollinger-Ellison syndrome consists of a non-beta islet cell tumor secreting gastrin in association with acid hypersecretion and severe PUD, which occurs in approximately 90 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of Zollinger-Ellison tumors are sporadic. However, some occur in association with the multiple endocrine neoplasia syndrome type 1 (MEN1). MEN1 is a familial disorder characterized by an autosomal dominant predisposition to tumors of the parathyroid glands (which occur in nearly all patients by age 50), anterior pituitary, and pancreatic islet cells (gastrinoma or insulinoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although gastrinoma-associated ulcers may be indistinguishable from ordinary peptic ulcers, several distinguishing features should raise the level of suspicion (",
"    <a class=\"graphic graphic_table graphicRef50291 \" href=\"UTD.htm?3/52/3916\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, the diagnosis of gastrinoma depends upon demonstrating hypergastrinemia in association with acid hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/33\">",
"     33",
"    </a>",
"    ]. It is important to stress that the majority of patients with hypergastrinemia have acid",
"    <strong>",
"     hypo",
"    </strong>",
"    secretion, with hypergastrinemia resulting from decreased acid feedback inhibition of gastrin release. Provocative testing is useful in patients in whom the elevation in serum gastrin concentration is not dramatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mastocytosis is characterized by mast cell infiltration of many tissues and symptoms of flushing, pruritus, abdominal pain, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Dyspepsia, duodenal ulcers, and severe duodenitis occur in 30 to 50 percent of cases and can be associated with basal acid hypersecretion, a presentation sometimes reminiscent of gastrinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/34\">",
"     34",
"    </a>",
"    ]. Serum histamine concentrations may be elevated, particularly in the setting of ulcer disease, suggesting that circulating histamine contributes to basal acid hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Consistent with this hypothesis is the observation that the dyspeptic symptoms and duodenal disease are readily treated by an H2 receptor antagonist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Carcinoid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an association of carcinoid syndrome with peptic ulcer that is probably related to ectopic histamine production [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/36\">",
"     36",
"    </a>",
"    ]. The ulcer syndrome can usually be controlled with H2 receptor antagonists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Basophilia in myeloproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid hypersecretion, an increased risk of peptic ulcer, and elevated serum histamine concentrations occur in myeloproliferative disorders associated with basophilia such as basophilic leukemia and chronic myeloid leukemia with marked basophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/37\">",
"     37",
"    </a>",
"    ]. Acid hypersecretion may only occur when basophilia reaches a threshold level or cell lysis occurs during chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polycythemia vera has also been associated with peptic disease. The precipitating cause may be reduced mucosal blood flow due to increased viscosity. Although modest basophilia occurs in polycythemia vera, circulating histamine levels are probably too low to induce ulcer formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antral G cell hyperfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-",
"    <em>",
"     H. pylori",
"    </em>",
"    era, an entity called antral G cell hyperfunction was reported, characterized by duodenal ulcers, increased basal-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meal-stimulated gastrin release, and usually increased basal or maximal acid output [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It now appears probable that antral G cell hyperfunction usually reflects an exaggerated response to",
"    <em>",
"     H. pylori",
"    </em>",
"    -induced hypergastrinemia, being part of the spectrum of",
"    <em>",
"     H. pylori",
"    </em>",
"    -associated duodenal ulcers. In",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive patients who appear to have this disorder, anti-",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy induces ulcer healing and suppresses serum gastrin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although controversial and rare, antral G cell hyperfunction can probably occur in the absence of",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. The pathogenesis of hypergastrinemia in this setting is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Post-gastric surgery and post-procedure ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antral exclusion (retained gastrin antrum) is a rare cause of peptic ulcers. It has been described in patients after gastric resection when some antral mucosa was retained in the duodenal pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stomal (marginal) ulcers involving the small intestinal mucosa occur in 1 to 16 percent of patients 3 to 18 months after Roux-en-Y gastric bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. Patients present with pain, bleeding, or perforation. Acid hypersecretion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/43\">",
"     43",
"    </a>",
"    ],",
"    <em>",
"     H. pylori",
"    </em>",
"    , and non-absorbable suture material [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/44\">",
"     44",
"    </a>",
"    ] have been hypothesized to play a role in pathogenesis. In one study, patients who had",
"    <em>",
"     H. pylori",
"    </em>",
"    cured before surgery had an increased risk of postoperative marginal ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a study from Taiwan found no role for",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/47\">",
"     47",
"    </a>",
"    ]. Anecdotal experience suggests that a PPI combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    prevents further recurrence and need for re-operation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric ulcers in the upper portion of the lesser curvature were observed in 4 of 180 patients undergoing laparoscopic fundoplication for gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/48\">",
"     48",
"    </a>",
"    ]; a role for",
"    <em>",
"     H. pylori",
"    </em>",
"    was hypothesized in this study from Japan, but the numbers were too small to draw any conclusions.",
"   </p>",
"   <p>",
"    Peptic ulceration has also been observed in association with foreign bodies. Microcoils from previous gastroduodenal artery embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/49\">",
"     49",
"    </a>",
"    ] and surgical clip migration from prior laparoscopic cholecystectomy have been found in ulcer craters [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, a retrospective study found that 2.5 percent of 1095 patients undergoing laparoscopic Roux-en-Y gastric bypass surgery developed marginal ulceration during a period when nonabsorbable suture material was used for the inner layer of the anastomosis; subsequently, the rate decreased to 1.3 percent in 2190 patients in whom absorbable suture was used. Furthermore, visible suture material was observed endoscopically at the ulcer site more often in patients who received nonabsorbable sutures (64 versus 3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093026\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093045\">",
"    <span class=\"h3\">",
"     Isolated duodenal H. pylori colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A provocative, but as yet unconfirmed, Italian study found that 42 of 608 patients (6.9 percent) with duodenal ulcer had no other obvious cause; 18 of these 42 patients had isolated duodenal colonization with",
"    <em>",
"     H. pylori",
"    </em>",
"    detected by biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/51\">",
"     51",
"    </a>",
"    ].",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication therapy was given to these 18 subjects; two had ulcer recurrences compared with 14 out of 20 subjects in the \"idiopathic\" group. Urea breath tests were positive in only three of the 18 patients with isolated duodenal colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/51\">",
"     51",
"    </a>",
"    ]. Therefore, especially in high prevalence regions for",
"    <em>",
"     H. pylori",
"    </em>",
"    , it is important to consider duodenal colonization in patients who lack gastric evidence of",
"    <em>",
"     H. pylori",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Herpes simplex virus type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible involvement of Herpes simplex virus type 1 (HSV-1) in patients with peptic ulcer has been suggested by an increased incidence of anti-HSV-1 antibodies in patients with peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/52,53\">",
"     52,53",
"    </a>",
"    ] and the detection of DNA and protein specific for HSV-1 in the mucosa at the ulcer margin in a small proportion of patients with seemingly ordinary ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. In contrast, these HSV markers were not detected in tissue at a distance from the ulcer margin, in mucosal specimens from most patients with peptic ulcer, and in all tested nonulcer subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. The patients with HSV-1 markers had antral or prepyloric ulcers; none had systemic disease or evidence of compromised immune function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study using PCR to identify HSV-I and a CLO-test and histology to identify",
"    <em>",
"     H. pylori",
"    </em>",
"    found HSV-I in 30 and 32 percent of duodenal and gastric ulcers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/55\">",
"     55",
"    </a>",
"    ]. HSV-I was found more frequently in the absence of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection. In all three studies, HSV-1 was present only in the margin of ulcers and was absent in gastric mucosa distant from the ulcer and in controls, implicating HSV-1 in ulcer pathogenesis.",
"   </p>",
"   <p>",
"    There is some evidence that the pathogenesis may involve infected enteric neurons. HSV-1 was found localized in clusters of cells near the margin of the ulcer; these cells were of neuroendocrine origin and innervated by the vagus nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an animal model, oral inoculation of immune deficient mice with HSV-1 resulted in viral replication and persistence almost exclusively in enteric neurons and their processes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/56\">",
"     56",
"    </a>",
"    ]. More than 50 percent of these mice had gastric ulcers, but only 1 of 40 contained viral antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cytomegalovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) has been associated with PUD in immunocompromised patients in whom it can cause large, shallow ulcers of the stomach and esophagus. CMV associated PUD has also been described in nonimmunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/57-62\">",
"     57-62",
"    </a>",
"    ]. The ulcers in these patients were all gastric and usually multiple. The diagnosis has been made by finding intranuclear inclusion bodies or CMV-DNA in the gastric mucosa in biopsy specimens taken from the ulcerous region. However, this association must be rare, considering the frequency with which CMV infection and peptic ulcers are encountered independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093118\">",
"    <span class=\"h3\">",
"     Rare infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other very uncommon fungal, parasitic, and mycobacterial infections can also cause gastroduodenal ulceration and deserve consideration in",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative, NSAID-negative ulcers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of peptic ulcer disease\", section on 'Infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mechanical: Duodenal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual cases of duodenal ulcers have been linked to a variety of duodenal abnormalities, including congenital duodenal webs, hypertrophic pyloric stenosis, annular pancreas (a rare congenital disorder in which pancreatic tissue encircles the second portion of the duodenum), and a preduodenal portal vein. Duodenal ulcers in these settings may present in infancy or childhood, but can also occur in adolescence or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/63\">",
"     63",
"    </a>",
"    ]. As an example, although annular pancreas can present at birth with high-grade duodenal obstruction, it more commonly presents in the second to seventh decade, with the peak incidence in the between the ages of 30 and 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Ulcers with annular pancreas are often postbulbar and can be associated with basal acid hypersecretion, although mechanisms linking these various \"obstructing\" lesions of the pylorus and duodenum to acid hypersecretion and ulcer disease remain undefined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18293?source=see_link\">",
"     \"Annular pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vascular causes, crack cocaine, and methamphetamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal blood flow is critical to mucosal integrity. Although ischemia is rare because of the rich vascularization of the gastroduodenal mucosa, vascular insufficiency syndromes involving arterial supply do rarely present with peptic ulceration that is unrelated to",
"    <em>",
"     H. pylori",
"    </em>",
"    infection or NSAID use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Some patients complain of typical ulcer pain, while others may have symptoms suggestive of mesenteric angina with pain following meals. Endoscopy may reveal multiple gastric or duodenal ulcers. Ulcers related to vascular stenosis often fail PPI therapy, but several reports indicated response to revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. Gastroduodenal artery pseudoaneurysm is also a rare cause of ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mucosal vasoconstriction may explain the perforation of gastroduodenal ulcers that have been described with crack cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. One study retrospectively evaluated 78 consecutive patients undergoing emergency surgical management for PUD over a six-year period at a large inner city municipal teaching hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/72\">",
"     72",
"    </a>",
"    ]. Confirmation of crack cocaine usage within eight hours of clinical presentation was obtained in 24 patients (31 percent). Duodenal ulcer perforation was more common in the users of crack cocaine (75 versus 46 percent in patients with no antecedent history of crack cocaine use). Omental patching of these ulcers has been recommended as the procedure of choice, and can be performed via laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recent use of cocaine or amphetamines also appears to be a risk factor for giant gastric and duodenal ulcers (greater than 2 to 3 cm in greatest dimension) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enterocolic lymphocytic phlebitis is a rare cause of gastrointestinal ischemia apparently due to inflammation. It usually involves the intestine, but one case had gastric and duodenal involvement associated with a chronic non-healing antral ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal ulceration can occur after abdominal radiotherapy, with the second portion of the duodenum being especially sensitive to radiation injury. Two cases resistant to H2 receptor antagonists responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , supporting the classification of these lesions as a specific form of \"peptic\" ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/77\">",
"     77",
"    </a>",
"    ]. Gastroduodenal ulceration also occurs following radioembolization used to treat hepatic tumors with an incidence between 3 and 5 percent; abdominal pain, nausea, vomiting, and anorexia herald this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. Careful attention to protocol may reduce the risks of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093401\">",
"    <span class=\"h2\">",
"     Inflammatory and infiltrating disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the stomach is the most common site of sarcoidosis in the gastrointestinal tract, almost always occurring in association with pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Ulceration resembling PUD can occur with or without enlargement of mucosal folds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093433\">",
"    <span class=\"h3\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease of the stomach",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duodenum is not infrequently found [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/83\">",
"     83",
"    </a>",
"    ] but only occasionally causes clinical impact. In the large majority of cases, more distal Crohn's disease is also evident. Involvement presents with obstruction, ulceration, fistula formation, or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093441\">",
"    <span class=\"h3\">",
"     Other gastroenteritides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports indicate that peptic ulcers, including perforated ulcers, can occur in association with eosinophilic gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/85-87\">",
"     85-87",
"    </a>",
"    ] and hypereosinophilic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/88\">",
"     88",
"    </a>",
"    ] in the absence of any other apparent cause. Refractory gastric ulcer has also been associated with abundant IgG4-positive plasma cell infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093422\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093547\">",
"    <span class=\"h3\">",
"     Idiopathic hypersecretory duodenal ulcer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of patients with duodenal ulcers have basal acid output above 15",
"    <span class=\"nowrap\">",
"     mmol/h,",
"    </span>",
"    the absence of hypergastrinemia, and ulcer disease unrelated to",
"    <em>",
"     H. pylori",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/90\">",
"     90",
"    </a>",
"    ]. These cases appear to represent a form of hypersecretory duodenal ulcer, the mechanisms of which remain to be defined. The acid hypersecretion appears to respond to long-term treatment with a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Such patients may require relatively high doses of a PPI, as in gastrinoma. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small subset of ulcers are not associated with any recognized cause and are called \"idiopathic\". This category includes ulcers that persist after successful cure of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection. One possible etiologic factor deserves consideration. It is well recognized that a portion of the population develop intense scarring following skin injury (keloids) or abdominal surgery. Dense scarring is also found in association with some peptic ulcers and may prevent normal healing by preventing ingrowth of new blood vessels. It is not known whether this pattern reflects specific pathogenic factors or an individual variation in response to chronic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ULCERS DUE TO COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a longstanding suspicion that peptic ulcer is associated with other medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/92\">",
"     92",
"    </a>",
"    ]. However, the existence, mechanisms, and implications of these associations remain controversial. Many such apparent associations may be spurious and due to chance, selection and ascertainment bias, and failure to consider confounding variables such as",
"    <em>",
"     H. pylori",
"    </em>",
"    infection, nonsteroidal antiinflammatory drugs (NSAIDs), and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher prevalence of peptic ulcer disease (PUD) in association with comorbidities has generally been reported in studies performed in a hospital or referral population compared with those examining a random population.",
"     </li>",
"     <li>",
"      Patients undergoing medical evaluation are more likely to have other conditions such as PUD discovered.",
"     </li>",
"     <li>",
"      Other causes of PUD may not have been adequately excluded. For example, false-negative tests for",
"      <em>",
"       H. pylori",
"      </em>",
"      are common, especially if only a single test is done. Similarly, use of NSAIDs may not always be recognized, especially in retrospective studies.",
"     </li>",
"     <li>",
"      It is also important to distinguish the impact of medical comorbidity on ulcer prevalence, the risk of complications, and the morbidity and mortality from those complications. Comorbidity appears to impact each of these dimensions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"       \"Overview of the complications of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Stress ulcers in hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between medical comorbidity and peptic ulcer is generally accepted for \"stress ulcers\" that occur in an intensive care unit (ICU) setting. Superficial mucosal lesions are present in a majority of seriously ill patients within 18 hours of admission to the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/94\">",
"     94",
"    </a>",
"    ]. This finding has been called stress-related mucosal damage. However, although stress-related mucosal damage can cause low-grade gastrointestinal (GI) bleeding, it rarely causes clinically significant bleeding in the absence of severe coagulopathy. Serious complications result from discrete, deep ulcers that erode into sizable blood vessels or perforate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Comorbid peptic ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology underlying stress-ulcer formation in the ICU may also apply to settings outside of the ICU. Among hospitalized patients not in the ICU, nosocomial GI bleeding occurred in 0.3 percent of patients in one large series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/95\">",
"     95",
"    </a>",
"    ]. Prophylaxis with acid suppressive medications appears to reduce the risk, but the number needed to treat to prevent one case of upper GI bleeding is very large. &nbsp;",
"   </p>",
"   <p>",
"    However, some medical conditions (both chronic and acute) may predispose to PUD by mechanisms that are incompletely understood. Contributing factors may be malnutrition and a catabolic state, with negative nitrogen balance interfering with tissue integrity and repair and tissue hypoperfusion and poor oxygenation due to hypovolemia, anemia, low vascular oncotic pressure, vasoconstriction, and poor oxygen delivery. The impairment of tissue repair and healing may be the most critical factor since mucosal damage is common in seriously ill patients. Disease-specific factors may also be important in some settings, but such factors have not been consistently identified, with the possible exception of cirrhosis (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Cirrhosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The following sections list several chronic conditions in which a possible association with PUD has been described:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of peptic ulcer is significantly increased in patients with cirrhosis, with prevalence estimates ranging from 10 to 49 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/96-99\">",
"     96-99",
"    </a>",
"    ]. The annual incidence has been estimated to be 4.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/100\">",
"     100",
"    </a>",
"    ]. Although peptic ulcers associated with cirrhosis are often asymptomatic, there is a high rate of complications and frequent recurrence.",
"   </p>",
"   <p>",
"    The mechanism of the association of peptic ulcer with cirrhosis is unknown. Alcohol ingestion is not an explanation, since there is no convincing evidence that alcohol per se is a risk factor for peptic ulcer and the association is evident for all forms of cirrhosis. Although some studies have implicated a role for",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/98,101\">",
"     98,101",
"    </a>",
"    ], other studies have not found an apparent association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/99\">",
"     99",
"    </a>",
"    ]. More importantly, treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    with antibiotics had no impact; an indistinguishable, high ulcer recurrence rate was found for",
"    <em>",
"     H. pylori",
"    </em>",
"    -cured, persisting",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive, and",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/99\">",
"     99",
"    </a>",
"    ]. The Child-Pugh class is a risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/98\">",
"     98",
"    </a>",
"    ], suggesting that the severity of the cirrhosis is a factor.",
"   </p>",
"   <p>",
"    Yearly recurrence rates as high as 50 percent have been described, underlining the importance of careful follow-up for patients with cirrhosis and PUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/99\">",
"     99",
"    </a>",
"    ]. Although many of the recurrences are asymptomatic, the risk of complications is sufficiently high to warrant maintenance antisecretory therapy.",
"   </p>",
"   <p>",
"    <strong>",
"     Renal disease",
"    </strong>",
"    &mdash; The prevalence of peptic ulcer in chronic renal failure has been controversial, possibly impacted by the status and comorbidities of the patient, treatments including NSAIDs, antiplatelet agents, anticoagulants, and possibly",
"    <em>",
"     H. pylori",
"    </em>",
"    infection. In 198 patients studied within 11 days of starting hemodialysis, ulcers were found in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/102\">",
"     102",
"    </a>",
"    ]. In another study from Taiwan, 18.5 percent of 827 dialysis patients with no history of prior peptic ulcer had new onset peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/103\">",
"     103",
"    </a>",
"    ]. Age, peritoneal dialysis (versus hemodialysis), diabetes mellitus, heart failure, and low serum albumin were identified as significant risk factors in multivariable analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/103\">",
"     103",
"    </a>",
"    ]. Patients with stress ulceration following acute events, such as sepsis, pulmonary failure, or operation, were excluded from this analysis.",
"   </p>",
"   <p>",
"    The role of",
"    <em>",
"     H. pylori",
"    </em>",
"    is controversial; at most, it plays a role in a subset of patients. When 32 patients with peptic ulcer and chronic renal failure were followed for two years after",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication, there were eight ulcer recurrences (25 percent), whereas there were two recurrences among 64 peptic ulcer patients without renal failure who also had",
"    <em>",
"     H. pylori",
"    </em>",
"    eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/104\">",
"     104",
"    </a>",
"    ]. Interestingly, there were 28 recurrences among 48 renal failure patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative peptic ulcer. This study suggests that",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication will at most reduce, but not eliminate, recurrence rates in patients with chronic renal failure. There is very little information on treatment outcomes for patients with PUD and chronic renal failure. One study suggested that the prophylactic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    decreased the risk from ulceration in patients on maintenance hemodialysis except in patients who used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PUD remains a significant cause of morbidity posttransplantation due to several factors, including immunosuppression, the administration of glucocorticoids, and CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    may be an important risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, one report found independent risk factors for PUD were use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    pulse therapy and a pretransplantation history of PUD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/108\">",
"     108",
"    </a>",
"    ]. Thus, antiulcer prophylaxis is routine in most centers, but there are limited data from well-controlled trials to guide treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether pretransplantation screening for PUD is useful is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/110\">",
"     110",
"    </a>",
"    ]. We take a careful history for candidate symptoms and prior peptic ulcer, assess",
"    <em>",
"     H. pylori",
"    </em>",
"    status, and treat",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive subjects with antibiotics. We reserve upper endoscopy for patients with a prior ulcer history or who had been treated for",
"    <em>",
"     H. pylori",
"    </em>",
"    to confirm the absence of both ulcers and",
"    <em>",
"     H. pylori",
"    </em>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between chronic obstructive pulmonary disease (COPD) and peptic ulcers has been suspected for many years. The frequency of chronic lung disease in patients with peptic ulcer is increased two to three times over the general population and peptic ulcers, both gastric and duodenal, occur in up to 30 percent of patients with chronic lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/92,111,112\">",
"     92,111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between these diseases is not influenced by the clinical severity or therapy of the lung disease. The major factor underlying the association may be the impact of cigarette smoking on both diseases. In one series of Japanese men living in Hawaii, cigarettes were associated with an increased risk of gastric and duodenal ulcer, but showed a dose-response in pack-years only for gastric ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study using Taiwan&rsquo;s National Health Insurance research database that included 62,876 patients (32,682 patients with COPD and 30,194 age and gender matched controls without COPD) with eight years of follow-up, bleeding from peptic ulcers occurred in 2.9 percent of patients with COPD and in 1.7 percent of patients without COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/113\">",
"     113",
"    </a>",
"    ]. After adjusting for age, sex, comorbidities, history of peptic ulcer disease, and NSAID use, COPD appeared to be an independent risk factor for peptic ulcer bleeding (adjusted hazard ratio 1.93, 95% CI 1.73-2.17). Unfortunately, the database did not contain information on smoking or H. pylori, therefore precluding any conclusions about whether this relation between COPD and peptic ulcer bleeding was direct or indirect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093842\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Admissions for complicated ulcer disease are significantly higher for diabetic patients than for controls. In one study, predictors of hospital admission included age, kidney function, non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    anticoagulant use, sulfonylurea therapy, peripheral vascular disease, and diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Rheumatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer prevalence is markedly increased in patients with rheumatic disease due to the use of NSAIDs. It has been estimated that the point prevalence of ulcers in patients on long-term NSAID treatment approximates 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/115\">",
"     115",
"    </a>",
"    ]. However, many of these ulcers are endoscopic ulcers and will not present as clinical ulcer events. For this reason, consideration should be given to prophylaxis (eg, with a proton pump inhibitor or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ), but only in high risk patients. There is no evidence for any association independent of NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19093878\">",
"    <span class=\"h3\">",
"     Other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of 240 patients with celiac disease found 12 percent had either a gastric or duodenal ulcer diagnosed, three quarters of whom were",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/0/19466/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before considering unusual causes of peptic ulcer disease (PUD),",
"      <em>",
"       H. pylori",
"      </em>",
"      and nonsteroidal antiinflammatory drug (NSAID) use should be excluded since these two risk factors still account for the large majority of cases of PUD. False-negative testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      and a failure to detect NSAID use are probably the most common causes of apparently",
"      <em>",
"       H. pylori",
"      </em>",
"      -negative, NSAID-negative ulcers. For",
"      <em>",
"       H. pylori",
"      </em>",
"      , particular caution is needed because many of the patients being evaluated will have been treated with a proton pump inhibitor (PPI) or antibiotics, rendering tests dependent upon bacterial density less reliable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .) In patients with refractory or complicated ulcers, in addition to a careful history, serum salicylate levels may be useful in detecting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      abuse.",
"     </li>",
"     <li>",
"      Less common causes (",
"      <a class=\"graphic graphic_table graphicRef79691 \" href=\"UTD.htm?4/40/4749\">",
"       table 2",
"      </a>",
"      ) are likely to take on increasing relative importance because of the rapid decline in",
"      <em>",
"       H. pylori",
"      </em>",
"      infection in developed countries, the availability of NSAIDs with lower risk of ulcer complications, and the use of concomitant therapies (such as PPIs), which reduce ulcer risk under most circumstances. An approach to patients in whom these diagnoses are considered should be based upon the clinical suspicion for a particular diagnosis and appropriate diagnostic testing when needed (",
"      <a class=\"graphic graphic_table graphicRef75002 \" href=\"UTD.htm?11/34/11820\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With the exception of acid hypersecretory states where it is clear that titrating PPI therapy is fully effective, there have been no rigorous studies of treatment of non-",
"      <em>",
"       H. pylori",
"      </em>",
"      , non-NSAID ulcer disease. PPI therapy provides the best option, although effectiveness is likely to be compromised when the underlying cause cannot be reversed, such as with medical comorbidity or ischemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Initial approach to ulcers not due to H. pylori'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A growing list of drugs has been implicated in the development of upper gastrointestinal complications. These drugs should be avoided, if possible, in patients taking NSAIDS or who are at high risk for bleeding or ulcer complications and in patients with a past history of peptic ulcer. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Drugs other than NSAIDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As general rules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NSAIDs including low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      act synergistically with other ulcerogenic or antithrombotic agents to cause upper GI complications. Drugs implicated include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (in doses greater than 2 or 3 g daily), bisphosphonates, glucocorticoids, SSRIs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      has also been implicated but the risk has not been assessed in the setting of NSAIDs.",
"     </li>",
"     <li>",
"      The risk of some agents may only be evident in patients with an ulcer or bleeding diathesis, such as those with a prior history of PUD or bleeding complications.",
"     </li>",
"     <li>",
"      Potential GI risks of these drugs in patients taking NSAIDs or otherwise at increased risk for GI complications should be considered. Strategies to reduce the risk of GI complications in patients taking these agents have not been well studied, although PPIs are likely to be effective. Potential drug interactions between PPIs and other medications may also influence treatment decisions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"       \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H32#H32\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Proton pump inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/1\">",
"      Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/2\">",
"      Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther 2009; 30:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/3\">",
"      Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/4\">",
"      Rahme E, Barkun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008; 103:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/5\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Hern&aacute;ndez-D&iacute;az S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/6\">",
"      Gonz&aacute;lez-P&eacute;rez A, Rodr&iacute;guez LA. Upper gastrointestinal complications among users of paracetamol. Basic Clin Pharmacol Toxicol 2006; 98:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/7\">",
"      Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011; 70:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/8\">",
"      Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/9\">",
"      Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002; 162:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/10\">",
"      Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/11\">",
"      Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 2009; 44:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/12\">",
"      Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/13\">",
"      Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/14\">",
"      Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/15\">",
"      Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant 2005; 19:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/16\">",
"      Molinari M, Al-Saif F, Ryan EA, et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005; 5:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/17\">",
"      Gulmez SE, Lassen AT, Aalykke C, et al. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. Br J Clin Pharmacol 2008; 66:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/18\">",
"      Verhamme K, Mosis G, Dieleman J, et al. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ 2006; 333:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/19\">",
"      Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/20\">",
"      Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/21\">",
"      Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/22\">",
"      Dunn NR, Pearce GL, Shakir SA. Association between SSRIs and upper gastrointestinal bleeding. SSRIs are no more likely than other drugs to cause such bleeding. BMJ 2000; 320:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/23\">",
"      Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/24\">",
"      Vidal X, Ib&aacute;&ntilde;ez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf 2008; 31:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/25\">",
"      de Abajo FJ, Garc&iacute;a-Rodr&iacute;guez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/26\">",
"      Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/27\">",
"      Gasse C, Christensen S, Riis A, et al. Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scand J Gastroenterol 2009; 44:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/28\">",
"      Shike M, Gillin JS, Kemeny N, et al. Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer. Am J Gastroenterol 1986; 81:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/29\">",
"      Ter Heine R, Fanggiday JC, Lankheet NA, et al. Erlotinib and pantoprazole: a relevant interaction or not? Br J Clin Pharmacol 2010; 70:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/30\">",
"      Togashi Y, Masago K, Fujita S, et al. Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. Lung Cancer 2011; 74:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/31\">",
"      Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res 2008; 14:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/32\">",
"      Reckamp K, Gitlitz B, Chen LC, et al. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer. Cancer 2011; 117:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/33\">",
"      Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/34\">",
"      Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study. Gastroenterology 1988; 95:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/35\">",
"      Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/36\">",
"      Wareing TH, Sawyers JL. Carcinoids and the carcinoid syndrome. Am J Surg 1983; 145:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/37\">",
"      Anderson W, Helman CA, Hirschowitz BI. Basophilic leukemia and the hypersecretion of gastric acid and pepsin. Gastroenterology 1988; 95:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/38\">",
"      Cooper RG, Dockray GJ, Calam J, Walker R. Acid and gastrin responses during intragastric titration in normal subjects and duodenal ulcer patients with G-cell hyperfunction. Gut 1985; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/39\">",
"      Annibale B, De Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/40\">",
"      Annibale B, Rindi G, D'Ambra G, et al. Antral gastrin cell hyperfunction and Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/41\">",
"      Kwan CP, Tytgat GN. Antral G-cell hyperplasia: a vanishing disease? Eur J Gastroenterol Hepatol 1995; 7:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/42\">",
"      Gibril F, Lindeman RJ, Abou-Saif A, et al. Retained gastric antrum syndrome: a forgotten, treatable cause of refractory peptic ulcer disease. Dig Dis Sci 2001; 46:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/43\">",
"      Hedberg J, Hedenstr&ouml;m H, Nilsson S, et al. Role of gastric acid in stomal ulcer after gastric bypass. Obes Surg 2005; 15:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/44\">",
"      Rasmussen JJ, Fuller W, Ali MR. Marginal ulceration after laparoscopic gastric bypass: an analysis of predisposing factors in 260 patients. Surg Endosc 2007; 21:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/45\">",
"      Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery. Surg Obes Relat Dis 2006; 2:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/46\">",
"      Sacks BC, Mattar SG, Qureshi FG, et al. Incidence of marginal ulcers and the use of absorbable anastomotic sutures in laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2006; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/47\">",
"      Yang CS, Lee WJ, Wang HH, et al. The influence of Helicobacter pylori infection on the development of gastric ulcer in symptomatic patients after bariatric surgery. Obes Surg 2006; 16:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/48\">",
"      Omura N, Kashiwagi H, Yano F, et al. Gastric ulcer after laparoscopic fundoplication for gastroesophageal reflux disease: significance of the eradication of Helicobacter pylori. Surg Laparosc Endosc Percutan Tech 2007; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/49\">",
"      Craig DG, Sebastian S, Hashmi S. Electronic clinical challenges and images in GI. Duodenal ulcer owing to erosion of microcoils from previous gastroduodenal artery embolization. Gastroenterology 2008; 135:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/50\">",
"      Samim MM, Armstrong CP. Surgical clip found at duodenal ulcer after laparoscopic cholecystectomy: report of a case. Int J Surg 2008; 6:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/51\">",
"      Pietroiusti A, Forlini A, Magrini A, et al. Isolated H. pylori duodenal colonization and idiopathic duodenal ulcers. Am J Gastroenterol 2008; 103:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/52\">",
"      L&ouml;hr JM, Nelson JA, Oldstone MB. Is herpes simplex virus associated with peptic ulcer disease? J Virol 1990; 64:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/53\">",
"      Archimandritis A, Markoulatos P, Tjivras M, et al. Herpes simplex virus types 1 and 2 and cytomegalovirus in peptic ulcer disease and non-ulcer dyspepsia. Hepatogastroenterology 1992; 39:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/54\">",
"      Kemker BP Jr, Docherty JJ, De Lucia A, et al. Herpes simplex virus: a possible etiologic agent in some gastroduodenal ulcer disease. Am Surg 1992; 58:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/55\">",
"      Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, et al. Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol 2005; 11:6644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/56\">",
"      Gesser RM, Valyi-Nagy T, Fraser NW, Altschuler SM. Oral inoculation of SCID mice with an attenuated herpes simplex virus-1 strain causes persistent enteric nervous system infection and gastric ulcers without direct mucosal infection. Lab Invest 1995; 73:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/57\">",
"      Arnar DO, Gudmundsson G, Theodors A, et al. Primary cytomegalovirus infection and gastric ulcers in normal host. Dig Dis Sci 1991; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/58\">",
"      Suzuki M, Ochi Y, Hosokawa S, et al. A multiple gastric ulcer case caused by cytomegalovirus infection. Tokushima J Exp Med 1996; 43:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/59\">",
"      Campbell DA, Piercey JR, Shnitka TK, et al. Cytomegalovirus-associated gastric ulcer. Gastroenterology 1977; 72:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/60\">",
"      Andrade Jde S, Bambirra EA, Lima GF, et al. Gastric cytomegalic inclusion bodies diagnosed by histologic examination of endoscopic biopsies in patients with gastric ulcer. Am J Clin Pathol 1983; 79:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/61\">",
"      Yokose N, Tanabe Y, An E, et al. Acute gastric mucosal lesions associated with cytomegalovirus infection in a non-immunocompromised host. Intern Med 1995; 34:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/62\">",
"      ter Meulen CG, Stronkhorst A, Tan I, Bravenboer B. Cytomegalovirus-associated gastric ulcers in a patient with celiac disease: coincidence or association? Am J Gastroenterol 1997; 92:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/63\">",
"      Naylor RG, Juler GL. Congenital causes of duodenal ulcers in adults. Arch Surg 1976; 111:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/64\">",
"      Urayama S, Kozarek R, Ball T, et al. Presentation and treatment of annular pancreas in an adult population. Am J Gastroenterol 1995; 90:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/65\">",
"      Somin M, Korotinski S, Attali M, et al. Three cases of chronic mesenteric ischemia presenting as abdominal pain and Helicobacter pylori-negative gastric ulcer. Dig Dis Sci 2004; 49:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/66\">",
"      G&oacute;mez-Rubio M, Opio V, Ac&iacute;n F, et al. Chronic mesenteric ischemia: a cause of refractory duodenal ulcer. Am J Med 1995; 98:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/67\">",
"      Patel VK, Barrison I, Jackson J, Catnach S. Gastric ulceration due to chronic mesenteric ischaemia treated by stenting of the inferior mesenteric artery. Gut 2005; 54:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/68\">",
"      Becker S, Bonderup OK, Fonslet TO. Ischaemic gastric ulceration with endoscopic healing after revascularization. Eur J Gastroenterol Hepatol 2006; 18:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/69\">",
"      Elazary R, Abu-Gazala M, Schlager A, et al. Therapeutic angiography for giant bleeding gastro-duodenal artery pseudoaneurysm. World J Gastroenterol 2010; 16:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/70\">",
"      Lee HS, LaMaute HR, Pizzi WF, et al. Acute gastroduodenal perforations associated with use of crack. Ann Surg 1990; 211:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/71\">",
"      Abramson DL, Gertler JP, Lewis T, Kral JG. Crack-related perforated gastropyloric ulcer. J Clin Gastroenterol 1991; 13:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/72\">",
"      Sharma R, Organ CH Jr, Hirvela ER, Henderson VJ. Clinical observation of the temporal association between crack cocaine and duodenal ulcer perforation. Am J Surg 1997; 174:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/73\">",
"      Arrillaga A, Sosa JL, Najjar R. Laparoscopic patching of crack cocaine-induced perforated ulcers. Am Surg 1996; 62:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/74\">",
"      Kram HB, Hardin E, Clark SR, Shoemaker WC. Perforated ulcers related to smoking \"crack\" cocaine. Am Surg 1992; 58:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/75\">",
"      Pecha RE, Prindiville T, Pecha BS, et al. Association of cocaine and methamphetamine use with giant gastroduodenal ulcers. Am J Gastroenterol 1996; 91:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/76\">",
"      Abraham SC, Solem CA, Hauser SC, Smyrk TC. Chronic antral ulcer associated with gastroduodenal lymphocytic phlebitis. Am J Surg Pathol 2004; 28:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/77\">",
"      Koop H, Koop I, Klein M, et al. Irradiation-induced duodenal ulcer disease refractory to ranitidine: healing by omeprazole. J Clin Gastroenterol 1989; 11:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/78\">",
"      Naymagon S, Warner RR, Patel K, et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig Dis Sci 2010; 55:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/79\">",
"      Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc 2009; 70:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/80\">",
"      South CD, Meyer MM, Meis G, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol 2008; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/81\">",
"      Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral ulcers in gastric sarcoid. J Clin Gastroenterol 1997; 24:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/82\">",
"      Farman J, Ramirez G, Rybak B, et al. Gastric sarcoidosis. Abdom Imaging 1997; 22:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/83\">",
"      Oberhuber G, Hirsch M, Stolte M. High incidence of upper gastrointestinal tract involvement in Crohn's disease. Virchows Arch 1998; 432:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/84\">",
"      Yamamoto T, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease: clinicopathologic features and management. Scand J Gastroenterol 1999; 34:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/85\">",
"      Siaw EK, Sayed K, Jackson RJ. Eosinophilic gastroenteritis presenting as acute gastric perforation. J Pediatr Gastroenterol Nutr 2006; 43:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/86\">",
"      Chehade M, Sicherer SH, Magid MS, et al. Multiple exudative ulcers and pseudopolyps in allergic eosinophilic gastroenteritis that responded to dietary therapy. J Pediatr Gastroenterol Nutr 2007; 45:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/87\">",
"      Tee HP, Swartz D, Tydd T, Leong RW. Gastrointestinal: Eosinophilic enteritis manifesting as brown-pigmented duodenal ulcers. J Gastroenterol Hepatol 2009; 24:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/88\">",
"      Park TY, Choi CH, Yang SY, et al. A case of hypereosinophilic syndrome presenting with intractable gastric ulcers. World J Gastroenterol 2009; 15:6129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/89\">",
"      Fujita T, Ando T, Sakakibara M, et al. Refractory gastric ulcer with abundant IgG4-positive plasma cell infiltration: a case report. World J Gastroenterol 2010; 16:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/90\">",
"      Hirschowitz BI, Mohnen J, Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1996; 10:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/91\">",
"      Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/92\">",
"      Langman MJ, Cooke AR. Gastric and duodenal ulcer and their associated diseases. Lancet 1976; 1:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/93\">",
"      Donaldson RM. Factors complicating observed associations between peptic ulcer and other diseases. Gastroenterology 1975; 68:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/94\">",
"      Peura DA, Johnson LF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985; 103:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/95\">",
"      Herzig SJ, Vaughn BP, Howell MD, et al. Acid-suppressive medication use and the risk for nosocomial gastrointestinal tract bleeding. Arch Intern Med 2011; 171:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/96\">",
"      Siringo S, Burroughs AK, Bolondi L, et al. Peptic ulcer and its course in cirrhosis: an endoscopic and clinical prospective study. J Hepatol 1995; 22:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/97\">",
"      Vergara M, Calvet X, Roqu&eacute; M. Helicobacter pylori is a risk factor for peptic ulcer disease in cirrhotic patients. A meta-analysis. Eur J Gastroenterol Hepatol 2002; 14:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/98\">",
"      Kamalaporn P, Sobhonslidsuk A, Jatchavala J, et al. Factors predisposing to peptic ulcer disease in asymptomatic cirrhotic patients. Aliment Pharmacol Ther 2005; 21:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/99\">",
"      Lo GH, Yu HC, Chan YC, et al. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc 2005; 62:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/100\">",
"      Rabinovitz M, Schade RR, Dindzans V, et al. Prevalence of duodenal ulcer in cirrhotic males referred for liver transplantation. Does the etiology of cirrhosis make a difference? Dig Dis Sci 1990; 35:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/101\">",
"      Siringo S, Vaira D, Menegatti M, et al. High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer. Dig Dis Sci 1997; 42:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/102\">",
"      Kang JY, Ho KY, Yeoh KG, et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of Helicobacter pylori infection. J Gastroenterol Hepatol 1999; 14:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/103\">",
"      Chen YT, Yang WC, Lin CC, et al. Comparison of peptic ulcer disease risk between peritoneal and hemodialysis patients. Am J Nephrol 2010; 32:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/104\">",
"      Tseng GY, Lin HJ, Fang CT, et al. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. Aliment Pharmacol Ther 2007; 26:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/105\">",
"      Liang CC, Wang IK, Lin HH, et al. Prophylactic use of omeprazole associated with a reduced risk of peptic ulcer disease among maintenance hemodialysis patients. Ren Fail 2011; 33:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/106\">",
"      Benoit G, Moukarzel M, Verdelli G, et al. Gastrointestinal complications in renal transplantation. Transpl Int 1993; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/107\">",
"      Troppmann C, Papalois BE, Chiou A, et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. J Am Coll Surg 1995; 180:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/108\">",
"      Chen KJ, Chen CH, Cheng CH, et al. Risk factors for peptic ulcer disease in renal transplant patients--11 years of experience from a single center. Clin Nephrol 2004; 62:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/109\">",
"      Sk&aacute;la I, Mareckov&aacute; O, V&iacute;tko S, et al. Prophylaxis of acute gastroduodenal bleeding after renal transplantation. Transpl Int 1997; 10:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/110\">",
"      Reese J, Burton F, Lingle D, et al. Peptic ulcer disease following renal transplantation in the cyclosporine era. Am J Surg 1991; 162:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/111\">",
"      Kellow JE, Tao Z, Piper DW. Ventilatory function in chronic peptic ulcer. A controlled study of ventilatory function in patients with gastric and duodenal ulcer. Gastroenterology 1986; 91:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/112\">",
"      Stemmermann GN, Marcus EB, Buist AS, MacLean CJ. Relative impact of smoking and reduced pulmonary function on peptic ulcer risk. A prospective study of Japanese men in Hawaii. Gastroenterology 1989; 96:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/113\">",
"      Huang KW, Luo JC, Leu HB, et al. Chronic obstructive pulmonary disease: an independent risk factor for peptic ulcer bleeding: a nationwide population-based study. Aliment Pharmacol Ther 2012; 35:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/114\">",
"      Schimke K, Chubb SA, Davis WA, et al. Antiplatelet therapy, Helicobacter pylori infection and complicated peptic ulcer disease in diabetes: the Fremantle Diabetes Study. Diabet Med 2009; 26:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/115\">",
"      Hawkey CJ. The gastroenterologist's caseload: contribution of the rheumatologist. Semin Arthritis Rheum 1997; 26:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/0/19466/abstract/116\">",
"      Levine A, Domanov S, Sukhotnik I, et al. Celiac-associated peptic disease at upper endoscopy: how common is it? Scand J Gastroenterol 2009; 44:1424.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 23 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19466=[""].join("\n");
var outline_f19_0_19466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UNUSUAL CAUSES OF PEPTIC ULCER DISEASE AND UPPER GASTROINTESTINAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Drugs other than NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Acetaminophen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Spironolactone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19092613\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19092697\">",
"      Hormonal or mediator-induced, including secondary acid hypersecretory states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gastrinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Basophilia in myeloproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antral G cell hyperfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Post-gastric surgery and post-procedure ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19093026\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093045\">",
"      - Isolated duodenal H. pylori colonization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Herpes simplex virus type I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093118\">",
"      - Rare infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mechanical: Duodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vascular causes, crack cocaine, and methamphetamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19093401\">",
"      Inflammatory and infiltrating disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093433\">",
"      - Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093441\">",
"      - Other gastroenteritides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19093422\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093547\">",
"      - Idiopathic hypersecretory duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ULCERS DUE TO COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Stress ulcers in hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Comorbid peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093842\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19093878\">",
"      - Other diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/23\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/23|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/34/11820\" title=\"table 1\">",
"      Work-up for apparently H pylori-negative NSAID-negative ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/40/4749\" title=\"table 2\">",
"      Causes of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/52/3916\" title=\"table 3\">",
"      Conditions associated with ZES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18293?source=related_link\">",
"      Annular pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19113?source=related_link\">",
"      Epidemiology and etiology of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=related_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_0_19467="Bacterial pneumonia in HIV";
var content_f19_0_19467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60437&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of bacterial pneumonia in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Streptococcus pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Haemophilus influenzae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Non-typeable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Type B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptococcus, Group B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptococcus milleri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moraxella catarrhalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Klebsiella pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudomonas aeruginosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legionella species",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhodococcus equi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bordetella pertussis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nocardia asteroides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pasteurella multocida",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19467=[""].join("\n");
var outline_f19_0_19467=null;
var title_f19_0_19468="Causes of bacterial meningitis";
var content_f19_0_19468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic features of common causes of bacterial meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site of entry",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predisposing conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Neisseria meningitidis",
"        </em>",
"       </td>",
"       <td>",
"        Nasopharynx",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        Usually none, rarely complement deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"       <td>",
"        Nasopharynx, direct extension across skull fracture, or from contiguous or distant foci of infection",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        All conditions that predispose to pneumococcal bacteremia, fracture of cribriform plate, cochlear implants, CSF otorrhea from basilar skull fracture, defects of the ear ossicle (Mondini defect)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"       </td>",
"       <td>",
"        Gastrointestinal tract, placenta",
"       </td>",
"       <td>",
"        Elderly adults and neonates",
"       </td>",
"       <td>",
"        Defects in cell-mediated immunity (eg, glucocorticoids, transplantation [especially renal transplantation]), pregnancy, liver disease, alcoholism, malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulase-negative staphylococci",
"       </td>",
"       <td>",
"        Foreign body",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        Surgery and foreign body, especially ventricular drains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"       <td>",
"        Bacteremia, foreign body, skin",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        Endocarditis, surgery and foreign body, especially ventricular drains; cellulitis, decubitus ulcer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram-negative bacilli",
"       </td>",
"       <td>",
"        Various",
"       </td>",
"       <td>",
"        Elderly adults and neonates",
"       </td>",
"       <td>",
"        Advanced medical illness, neurosurgery, ventricular drains, disseminated strongyloidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"       </td>",
"       <td>",
"        Nasopharynx, contiguous spread from local infection",
"       </td>",
"       <td>",
"        Adults now, but infants and children if not vaccinated",
"       </td>",
"       <td>",
"        Diminished humoral immunity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19468=[""].join("\n");
var outline_f19_0_19468=null;
var title_f19_0_19469="Increased incidence of AF in subclinical hyperthyroidism";
var content_f19_0_19469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased incidence of atrial fibrillation in subclinical hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 240px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative incidence of atrial fibrillation in subjects over age 60 according to the serum concentration of thyrotropin (TSH). The risk of atrial fibrillation was increased almost threefold in the subjects with marked suppression of TSH (left panel) as compared with those who had normal serum TSH concentrations and were presumably euthyroid (right panel); patients with slightly low serum TSH concentrations (middle panel) had a lesser increase in risk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19469=[""].join("\n");
var outline_f19_0_19469=null;
var title_f19_0_19470="Triage radiation injury";
var content_f19_0_19470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Triage for radiation injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 428px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This flow chart details the triage and therapy for persons exposed to radiation in a scenario in which there are a limited number of casualties. The degree of toxicity to the variously defined organ systems (ie, cutaneous, gastrointestinal cerebrovascular, and hematologic, see separate figures) determines whether the patient is admitted to the hospital or monitored in an ambulatory setting. Patients with hematologic toxicity of grades 2 to 4 may be treated with transfusion of blood components, those with grades 3 to 4 may receive colony-stimulating factors, and those with grade 4 hematologic toxicity are potential candiates for hematopoietic cell transplantation.",
"    <div class=\"footnotes\">",
"     <br>",
"      * The highest degree of toxicity to any of these three organ system indicates the physiologic \"response category\" for an individual patient. All patients with hematologic toxicity of grade 2 or more require hospitalization.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dainiak, N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol 2002; 30:513. Copyright &copy; 2004 Elsevier Inc",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19470=[""].join("\n");
var outline_f19_0_19470=null;
var title_f19_0_19471="Coxa profunda in osteomalacia";
var content_f19_0_19471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coxa profunda abnormality in osteomalacia: Radiographic findings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone film in a patient with vitamin D resistant rickets showing hip deformity with coxa profunda (in which the femoral head comes deeply into the pelvis), coxa vara (in which the angle between the femoral neck and the femoral shaft is diminished) (arrow), and rods representing surgical treatment of pathologic fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of CJ Menkes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_0_19471=[""].join("\n");
var outline_f19_0_19471=null;
